Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
11beta-hydroxysteroid dehydrogenase (nad+) deficiency
Renin-Independent hypermineralocorticoidism.
11beta-hydroxysteroid dehydrogenase deficiency
Epidemiologic study of adrenal gland disorders in Japan.
17alpha-hydroxyprogesterone deacetylase deficiency
17-alpha-Hydroxylase deficiency: a case report with clinical and molecular analysis.
17alpha-hydroxyprogesterone deacetylase deficiency
17alpha-hydroxylase deficiency : biochemical and molecular findings in two sisters and their family.
17alpha-hydroxyprogesterone deacetylase deficiency
17alpha-hydroxylase deficiency accompanied by adrenal myelolipoma.
17alpha-hydroxyprogesterone deacetylase deficiency
17alpha-hydroxylase/17,20-lyase deficiency as a model to study enzymatic activity regulation: role of phosphorylation.
17alpha-hydroxyprogesterone deacetylase deficiency
17alpha-hydroxylase/17,20-lyase deficiency caused by a novel homozygous mutation (Y27Stop) in the cytochrome CYP17 gene.
17alpha-hydroxyprogesterone deacetylase deficiency
17alpha-hydroxylase/17,20-Lyase deficiency due to novel compound heterozygote mutations: treatment for tall stature in a female with male pseudohermaphroditism and spontaneous puberty in her affected sister.
17alpha-hydroxyprogesterone deacetylase deficiency
A 5'-splice site mutation in the cytochrome P450 steroid 17alpha-hydroxylase gene in 17alpha-hydroxylase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
A case of 17alpha-hydroxylase deficiency with symptoms mimicking testicular feminization.
17alpha-hydroxyprogesterone deacetylase deficiency
A complex heterozygous mutation of His373Leu and Asp487-Ser488-Phe489 deletion in human cytochrome P450c17 causes 17alpha-hydroxylase/17,20-lyase deficiency in three Chinese sisters.
17alpha-hydroxyprogesterone deacetylase deficiency
A compound heterozygous mutation in the CYP17 (17alpha-hydroxylase/17,20-lyase) gene in a Chinese subject with congenital adrenal hyperplasia.
17alpha-hydroxyprogesterone deacetylase deficiency
A male patient presenting with major clinical symptoms of glucocorticoid deficiency and skeletal dysplasia, showing a steroid pattern compatible with 17alpha-hydroxylase/17,20-lyase deficiency, but without obvious CYP17 gene mutations.
17alpha-hydroxyprogesterone deacetylase deficiency
A Missense Mutation in the Human Cytochrome b5 Gene causes 46,XY Disorder of Sex Development due to True Isolated 17,20 Lyase Deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
A novel compound heterozygous mutation in the CYP17 (P450 17alpha-hydroxylase) gene leading to 17alpha-hydroxylase/17,20-lyase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
A novel compound heterozygous mutation of K494_V495 deletion plus R496L and D487_F489 deletion in extreme C-terminus of cytochrome P450c17 causes 17alpha-hydroxylase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
A novel point mutation in P450c17 (CYP17) causing combined 17alpha-hydroxylase/17,20-lyase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
A young woman with hypogonadism, hypertension and hypokalaemia.
17alpha-hydroxyprogesterone deacetylase deficiency
Aldosterone-producing adenoma with prolonged amelioration by dexamethasone.
17alpha-hydroxyprogesterone deacetylase deficiency
Clinical, biochemical and genetic characteristics of children with congenital adrenal hyperplasia due to 17?-hydroxylase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Clinical, genetic and functional characteristics of three novel CYP17A1 mutations causing combined 17alpha-hydroxylase/17,20-lyase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Combined 17 alpha-hydroxylase/17,20-lyase deficiency due to a homozygous 25 BP duplication (NT 4157-4181) at exon 5 in the CYP17 resulting in a premature stop codon predicted by molecular modeling.
17alpha-hydroxyprogesterone deacetylase deficiency
Combined 17?-hydroxylase/17,20-lyase deficiency due to p.R96W mutation in the CYP17 gene in a Brazilian patient.
17alpha-hydroxyprogesterone deacetylase deficiency
Combined 17alpha-Hydroxylase/17,20-lyase deficiency caused by Phe93Cys mutation in the CYP17 gene.
17alpha-hydroxyprogesterone deacetylase deficiency
Compound heterozygous mutations (PHE53/54DEL and HIS373LEU) of the P450c17 gene result in a 17alpha-hydroxylase/17,20-lyase deficient male pseudohermaphrodite with unambiguous external genitalia.
17alpha-hydroxyprogesterone deacetylase deficiency
CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding.
17alpha-hydroxyprogesterone deacetylase deficiency
CYP17A1 deficient XY mice display susceptibility to atherosclerosis, altered lipidomic profile and atypical sex development.
17alpha-hydroxyprogesterone deacetylase deficiency
Differential inhibition of 17alpha-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Disorders of androgen synthesis--from cholesterol to dehydroepiandrosterone.
17alpha-hydroxyprogesterone deacetylase deficiency
Distinctive profile of the 17-hydroxylase and 17,20-lyase activities revealed by urinary steroid metabolomes of patients with CYP17 deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Early steps in androgen biosynthesis: from cholesterol to DHEA.
17alpha-hydroxyprogesterone deacetylase deficiency
Endocrine screening in 32 consecutive patients with hypospadias.
17alpha-hydroxyprogesterone deacetylase deficiency
Familial partial 17,20-desmolase and 17alpha-hydroxylase deficiency presenting as infertility.
17alpha-hydroxyprogesterone deacetylase deficiency
Female pattern hair loss in a patient with 17alpha-hydroxylase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Female phenotype with male karyotype: a clinical enigma.
17alpha-hydroxyprogesterone deacetylase deficiency
Genetic analysis of the cytochrome P-450c17alpha (CYP17) and aldosterone synthase (CYP11B2) in Japanese patients with 17alpha-hydroxylase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Genotyping of five chinese patients with 17alpha-hydroxylase deficiency diagnosed through high-performance liquid chromatography serum adrenal profile: identification of two novel CYP17 mutations.
17alpha-hydroxyprogesterone deacetylase deficiency
Hypertension and adrenal disorders.
17alpha-hydroxyprogesterone deacetylase deficiency
Hypertension due to 17alpha-hydroxylase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Hypokalemic crisis simulating intestinal obstruction in a 4-year-old girl. A consequence of 17alpha-hydroxylase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Identification of a novel splicing mutation and 1-bp deletion in the 17alpha-hydroxylase gene of Japanese patients with 17alpha-hydroxylase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Identification of steroid biosynthetic defects in genotype-proven heterozygous individuals for 17alpha-hydroxylase/17,20- lyase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Impairment of AVP regulation in 17alpha-hydroxylase deficiency, a unique form of adrenal insufficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Induction of endometrial cycles and ovulation in a woman with combined 17alpha-hydroxylase/17,20-lyase deficiency due to compound heterozygous mutations on the p45017alpha gene.
17alpha-hydroxyprogesterone deacetylase deficiency
Long term follow-up of a 46,XY phenotypic girl with 17alpha-hydroxylase deficiency treated with alternate-day dexamethasone.
17alpha-hydroxyprogesterone deacetylase deficiency
Loss of Cytochrome P450 17A1 Protein Expression in a 17alpha-Hydroxylase/17,20-Lyase-Deficient 46,XY Female Caused by Two Novel Mutations in the CYP17A1 Gene.
17alpha-hydroxyprogesterone deacetylase deficiency
Male pseudohermaphroditism with hypertension due to a 17alpha-hydroxylation deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Molecular basis of hypokalemic myopathy caused by 17alpha-hydroxylase/17,20-lyase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Mutation of proline 409 to arginine in the meander region of cytochrome p450c17 causes severe 17 alpha-hydroxylase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Mutational analysis of rare subtypes of congenital adrenal hyperplasia in a highly inbred population.
17alpha-hydroxyprogesterone deacetylase deficiency
New compound heterozygous mutation in the CYP17 gene in a 46,XY girl with 17 alpha-hydroxylase/17,20-lyase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
New, recurrent, and prevalent mutations: Clinical and molecular characterization of 26 Chinese patients with 17alpha-hydroxylase/17,20-lyase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Novel CYP17A1 mutation in a Japanese patient with combined 17alpha-hydroxylase/17,20-lyase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Novel human pathological mutations. Gene symbol: CYP17A1. Disease: 17alpha-hydroxylase/17,20-lyase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Novel mutation in cytochrome P450c17 causes complete combined 17alpha-hydroxylase/17,20-lyase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Novel mutation of the CYP17 gene in two unrelated patients with combined 17alpha-hydroxylase/17,20-lyase deficiency: demonstration of absent enzyme activity by expressing the mutant CYP17 gene and by three-dimensional modeling.
17alpha-hydroxyprogesterone deacetylase deficiency
Novel P450c17 mutation H373D causing combined 17alpha-hydroxylase/17,20-lyase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Ovarian hyperstimulation syndrome with low oestradiol in non-classical 17 alpha-hydroxylase, 17,20-lyase deficiency: what is the role of oestrogens?
17alpha-hydroxyprogesterone deacetylase deficiency
P450C17 (CYP17) Deficiency in Native Mexican Patient with a Novel Mutation.
17alpha-hydroxyprogesterone deacetylase deficiency
P450c17 Deficiency Caused by Compound Heterozygosity for Two Novel Mutations Presenting as Hypotension in Early Infancy.
17alpha-hydroxyprogesterone deacetylase deficiency
P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping.
17alpha-hydroxyprogesterone deacetylase deficiency
P450c17 deficiency: clinical and molecular characterization of six patients.
17alpha-hydroxyprogesterone deacetylase deficiency
Partial 17alpha-hydroxylase/17,20-lyase deficiency-clinical report of five Chinese 46,XX cases.
17alpha-hydroxyprogesterone deacetylase deficiency
Partial deficiency of 17?-hydroxylase/17,20-lyase caused by a novel missense mutation in the canonical cytochrome heme-interacting motif.
17alpha-hydroxyprogesterone deacetylase deficiency
Phenotype-genotype correlation in eight Chinese 17alpha-hydroxylase/17,20 lyase-deficiency patients with five novel mutations of CYP17A1 gene.
17alpha-hydroxyprogesterone deacetylase deficiency
Rare hypertension as a result of 17alpha-hydroxylase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Simultaneous determination of plasma 11-deoxycorticosterone, 18-hydroxy-11-deoxycorticosterone, and aldosterone in man.
17alpha-hydroxyprogesterone deacetylase deficiency
Spontaneous growth and bone age development in a patient with 17alpha-hydroxylase deficiency: evidence of the role of sexual steroids in prepubertal bone maturation.
17alpha-hydroxyprogesterone deacetylase deficiency
Steroid 17alpha-hydroxylase deficiency: first Australian case report.
17alpha-hydroxyprogesterone deacetylase deficiency
Steroidogenesis of the testis -- new genes and pathways.
17alpha-hydroxyprogesterone deacetylase deficiency
Subtle 17alpha-hydroxylase/17,20-lyase deficiency with homozygous Y201N mutation in an infertile woman.
17alpha-hydroxyprogesterone deacetylase deficiency
Targeted gene panel sequencing for molecular diagnosis of congenital adrenal hyperplasia.
17alpha-hydroxyprogesterone deacetylase deficiency
The genetics, pathophysiology, and management of human deficiencies of P450c17.
17alpha-hydroxyprogesterone deacetylase deficiency
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
17alpha-hydroxyprogesterone deacetylase deficiency
The molecular basis of isolated 17,20 lyase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
The regulation of 17,20 lyase activity.
17alpha-hydroxyprogesterone deacetylase deficiency
The role of adrenal steroidogenesis in arterial hypertension.
17alpha-hydroxyprogesterone deacetylase deficiency
The syndrome of 17,20 lyase deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
Two novel mutations found in a patient with 17alpha-hydroxylase enzyme deficiency.
17alpha-hydroxyprogesterone deacetylase deficiency
[17Alpha-hydroxylase deficiency]
17alpha-hydroxyprogesterone deacetylase deficiency
[A clinical and genetic analysis of a pedigree with two 46,XY patients suffering from 17alpha-hydroxylase deficiency]
17alpha-hydroxyprogesterone deacetylase deficiency
[Clinical and molecular genetic features of 17alpha-hydroxylase deficiency: study of a case]
17alpha-hydroxyprogesterone deacetylase deficiency
[Clinical characteristics of 17alpha-hydroxylase/17,20-lyase deficiency and long term follow up results.]
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Steroidogenesis of the testis -- new genes and pathways.
Abortion, Habitual
Genetic factors in fetal growth restriction and miscarriage.
Abortion, Habitual
Role of CYP17 and CYP19 polymorphisms in idiopathic recurrent miscarriages among South Indian women.
Abortion, Spontaneous
Genetic variation in the CYP17 gene and recurrent spontaneous abortions.
Acne Vulgaris
Association of the CYP17 MSP AI (T-34C) and CYP19 codon 39 (Trp/Arg) polymorphisms with susceptibility to acne vulgaris.
Acne Vulgaris
Gene variants associated with acne vulgaris presentation and severity: a systematic review and meta-analysis.
Acne Vulgaris
Polymorphisms in the cytochrome P-450 (CYP) 1A1 and 17 genes are not associated with acne vulgaris in the Polish population.
Acne Vulgaris
The relationship between CYP17 -34T/C polymorphism and acne in Chinese subjects revealed by sequencing.
Acne Vulgaris
[Correlation between CYP17 gene polymorphisms and female postadolescent acne in Han population in Hunan Province]
Addison Disease
3beta-hydroxysteroid dehydrogenase autoantibodies are rare in premature ovarian failure.
Addison Disease
Absence of autoantibodies connected to autoimmune polyendocrine syndrome type I and II and Addison's disease in girls and women with Turner syndrome.
Addison Disease
Adrenal-cortex autoantibodies and steroid-producing cells autoantibodies in patients with Addison's disease: comparison of immunofluorescence and immunoprecipitation assays.
Addison Disease
Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2.
Addison Disease
Autoantibodies against recombinant human steroidogenic enzymes 21-hydroxylase, side-chain cleavage and 17alpha-hydroxylase in Addison's disease and autoimmune polyendocrine syndrome type III.
Addison Disease
Autoantibodies to cytochrome P450 enzymes P450scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison's disease.
Addison Disease
Characterization of adrenal autoantigens recognized by sera from patients with autoimmune polyglandular syndrome (APS) type I.
Addison Disease
Epidemiologic study of adrenal gland disorders in Japan.
Adenocarcinoma
PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy.
Adenocarcinoma of Lung
EGFR L858R Mutation and Polymorphisms of Genes related to Estrogen Biosynthesis and Metabolism in Never-smoking Female Lung Adenocarcinoma Patients.
Adenoma
A Dispensable Role for P450(scc) in the Overproduction of Aldosterone in Aldosterone-Producing Adenoma and Idiopathic Hyperaldosteronism in Patients with Primary Aldosteronism.
Adenoma
A potential role for CPY17 as a parameter in differentiation between aldosterone-producing adenoma and nodular hyperplasia in patients with hyperaldosteronism.
Adenoma
ACTH-independent Cushing's syndrome with bilateral micronodular adrenal hyperplasia and ectopic adrenocortical adenoma.
Adenoma
Aldosterone-Producing Adenomas: Histopathology-Genotype Correlation and Identification of a Novel CACNA1D Mutation.
Adenoma
Benign cortisol-secreting adrenocortical adenomas produce small amounts of androgens.
Adenoma
Clinical characteristics of primary hyperaldosteronism due to adrenal microadenoma.
Adenoma
Disordered expression of adrenal steroidogenic P450 mRNAs in incidentally discovered nonfunctioning adrenal adenoma.
Adenoma
Editorial comment from Dr Fang to increased expression of CYP17 and CYP11B1 in subclinical Cushing's syndrome due to adrenal adenomas.
Adenoma
Editorial comment from Dr Ishidoya to increased expression of CYP17 and CYP11B1 in subclinical Cushing's syndrome due to adrenal adenomas.
Adenoma
Evaluation of Cortisol Production in Aldosterone-Producing Adenoma.
Adenoma
Expression of steroidogenic enzyme messenger ribonucleic acids and corticosteroid production in aldosterone-producing and "nonfunctioning" adrenal adenomas.
Adenoma
Expression profiles of COUP-TF, DAX-1, and SF-1 in the human adrenal gland and adrenocortical tumors: possible implications in steroidogenesis.
Adenoma
Genetic and Histopathologic Inter-Tumor Heterogeneity in Primary Aldosteronism.
Adenoma
Immunohistochemical study of cytochrome b5 in human adrenal gland and in adrenocortical adenomas from patients with Cushing's syndrome.
Adenoma
In vitro release of aldosterone and cortisol in human adrenal adenomas correlates to mRNA expression of steroidogenic enzymes for genes CYP11B2 and CYP17.
Adenoma
Increased expression of CYP17 and CYP11B1 in subclinical Cushing's syndrome due to adrenal adenomas.
Adenoma
Intratumoral heterogeneity of steroidogenesis in aldosterone-producing adenoma revealed by intensive double- and triple-immunostaining for CYP11B2/B1 and CYP17.
Adenoma
New aspects on primary aldosteronism.
Adenoma
Nuclear receptors and co-regulators in adrenal tumors.
Adenoma
Orphan receptors COUP-TF and DAX-1 as targets in disordered CYP17 expression in adrenocortical tumors.
Adenoma
Primary aldosteronism caused by a unilateral adrenal adenoma accompanied by autonomous cortisol secretion.
Adenoma
Regulation of differential COUP-TF-coregulator interactions in adrenal cortical steroidogenesis.
Adenoma
Role of the Mevalonate Pathway in Adrenocortical Tumorigenesis.
Adenomyosis
CYP17, CYP1A1 and COMT polymorphisms and the risk of adenomyosis and endometriosis in Taiwanese women.
Adenoviridae Infections
Regulation of androgen synthesis: the late steroidogenic pathway.
Adrenal Hyperplasia, Congenital
11Beta-Hydroxylase Deficiency and Other Syndromes of Mineralocorticoid Excess as a Rare Cause of Endocrine Hypertension.
Adrenal Hyperplasia, Congenital
17 alpha-Hydroxylase/17,20-lyase defects.
Adrenal Hyperplasia, Congenital
17-alpha-Hydroxylase deficiency: a case report with clinical and molecular analysis.
Adrenal Hyperplasia, Congenital
17-Hydroxyprogesterone deficiency as a cause of sexual infantilism and arterial hypertension: laboratory and molecular diagnosis--a case report.
Adrenal Hyperplasia, Congenital
17?-HYDROXYLASE DEFICIENCY IS AN UNDERDIAGNOSED DISEASE: HIGH FREQUENCY OF MISDIAGNOSES IN A LARGE COHORT OF BRAZILIAN PATIENTS.
Adrenal Hyperplasia, Congenital
17alpha-hydroxylase/17,20-lyase deficiency caused by a novel homozygous mutation (Y27Stop) in the cytochrome CYP17 gene.
Adrenal Hyperplasia, Congenital
46,XX DSD and Antley-Bixler syndrome due to novel mutations in the cytochrome P450 oxidoreductase gene.
Adrenal Hyperplasia, Congenital
A compound heterozygous mutation in the CYP17 (17alpha-hydroxylase/17,20-lyase) gene in a Chinese subject with congenital adrenal hyperplasia.
Adrenal Hyperplasia, Congenital
A new compound heterozygous mutation in the CYP17A1 gene in a female with 17?-hydroxylase/17,20-lyase deficiency.
Adrenal Hyperplasia, Congenital
A novel mutation in CYP17A1 gene leads to congenital adrenal hyperplasia: A case report.
Adrenal Hyperplasia, Congenital
A novel point mutation in P450c17 (CYP17) causing combined 17alpha-hydroxylase/17,20-lyase deficiency.
Adrenal Hyperplasia, Congenital
A review of the literature on common CYP17A1 mutations in adults with 17-hydroxylase/17,20-lyase deficiency, a case series of such mutations among Koreans and functional characteristics of a novel mutation.
Adrenal Hyperplasia, Congenital
A young woman with hypogonadism, hypertension and hypokalaemia.
Adrenal Hyperplasia, Congenital
Atypical presentation in patients with 17 ?-hydroxylase deficiency caused by a deletion in the CYP17A1 gene: short stature.
Adrenal Hyperplasia, Congenital
Canadian Mennonites and individuals residing in the Friesland region of The Netherlands share the same molecular basis of 17 alpha-hydroxylase deficiency.
Adrenal Hyperplasia, Congenital
Clinical characteristics and mutation analysis of two Chinese children with 17a-hydroxylase/17,20-lyase deficiency.
Adrenal Hyperplasia, Congenital
Clinical, biochemical and genetic characteristics of children with congenital adrenal hyperplasia due to 17?-hydroxylase deficiency.
Adrenal Hyperplasia, Congenital
Clinical, hormonal, ovarian, and genetic aspects of 46,XX patients with congenital adrenal hyperplasia due to CYP17A1 defects.
Adrenal Hyperplasia, Congenital
Combined 17 alpha-hydroxylase/17,20-lyase deficiency due to a homozygous 25 BP duplication (NT 4157-4181) at exon 5 in the CYP17 resulting in a premature stop codon predicted by molecular modeling.
Adrenal Hyperplasia, Congenital
Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study.
Adrenal Hyperplasia, Congenital
Delayed diagnosis of disorder of sex development (DSD) due to P450 oxidoreductase (POR) deficiency.
Adrenal Hyperplasia, Congenital
Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P.
Adrenal Hyperplasia, Congenital
Discordant Genotypic Sex and Phenotype Variations in Two Spanish Siblings with 17?-Hydroxylase/17,20-Lyase Deficiency Carrying the Most Prevalent Mutated CYP17A1 Alleles of Brazilian Patients.
Adrenal Hyperplasia, Congenital
Functional Identification of Compound Heterozygous Mutations in the CYP17A1 Gene Resulting in Combined 17?-Hydroxylase/17,20-Lyase Deficiency.
Adrenal Hyperplasia, Congenital
Genotyping of a Chinese family with 46,XX and 46,XY 17-hydroxylase deficiency.
Adrenal Hyperplasia, Congenital
Genotyping of five chinese patients with 17alpha-hydroxylase deficiency diagnosed through high-performance liquid chromatography serum adrenal profile: identification of two novel CYP17 mutations.
Adrenal Hyperplasia, Congenital
Homozygous CYP17A1 mutation (H373L) identified in a 46,XX female with combined 17?-hydroxylase/17,20-lyase deficiency.
Adrenal Hyperplasia, Congenital
Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect.
Adrenal Hyperplasia, Congenital
Hypertension and adrenal disorders.
Adrenal Hyperplasia, Congenital
Identification of a common molecular basis for combined 17 alpha-hydroxylase/17,20-lyase deficiency in two Mennonite families.
Adrenal Hyperplasia, Congenital
Identification of steroid biosynthetic defects in genotype-proven heterozygous individuals for 17alpha-hydroxylase/17,20- lyase deficiency.
Adrenal Hyperplasia, Congenital
Loss of Cytochrome P450 17A1 Protein Expression in a 17alpha-Hydroxylase/17,20-Lyase-Deficient 46,XY Female Caused by Two Novel Mutations in the CYP17A1 Gene.
Adrenal Hyperplasia, Congenital
New, recurrent, and prevalent mutations: Clinical and molecular characterization of 26 Chinese patients with 17alpha-hydroxylase/17,20-lyase deficiency.
Adrenal Hyperplasia, Congenital
Novel mutation in cytochrome P450c17 causes complete combined 17alpha-hydroxylase/17,20-lyase deficiency.
Adrenal Hyperplasia, Congenital
Novel mutation of the CYP17 gene in two unrelated patients with combined 17alpha-hydroxylase/17,20-lyase deficiency: demonstration of absent enzyme activity by expressing the mutant CYP17 gene and by three-dimensional modeling.
Adrenal Hyperplasia, Congenital
Novel P450c17 mutation H373D causing combined 17alpha-hydroxylase/17,20-lyase deficiency.
Adrenal Hyperplasia, Congenital
P450C17 (CYP17) Deficiency in Native Mexican Patient with a Novel Mutation.
Adrenal Hyperplasia, Congenital
P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping.
Adrenal Hyperplasia, Congenital
Prevalence of common mutations in the CYP17A1 gene in Chinese Han population.
Adrenal Hyperplasia, Congenital
Renin-Independent hypermineralocorticoidism.
Adrenal Hyperplasia, Congenital
Steroid 17alpha-hydroxylase deficiency: first Australian case report.
Adrenal Hyperplasia, Congenital
Steroid metabolism gene variants and their genotype-phenotype correlations in Chinese early-onset hypertension patients.
Adrenal Hyperplasia, Congenital
The broad phenotypic spectrum of 17?-hydroxylase/ 17,20-lyase (CYP17A1) deficiency: a case series.
Adrenal Hyperplasia, Congenital
The Glu331del mutation in the CYP17A1 gene causes atypical congenital adrenal hyperplasia in a 46,XX female.
Adrenal Hyperplasia, Congenital
Two intronic variants of CYP11B1 and CYP17A1 disrupt mRNA splicing and cause congenital adrenal hyperplasia (CAH).
Adrenal Hyperplasia, Congenital
Two novel mutations found in a patient with 17alpha-hydroxylase enzyme deficiency.
Adrenal Hyperplasia, Congenital
[Congenital adrenal hyperplasia due to lack of 17?-hydroxylase: A report of a new mutation in the gene CYP17A1.]
Adrenal Insufficiency
Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.
Adrenal Insufficiency
Combined homozygous 21 hydroxylase with heterozygous P450 oxidoreductase mutation in a Saudi boy presented with hypertension.
Adrenal Insufficiency
Cytochrome P450 oxidoreductase deficiency with Antley-Bixler syndrome: steroidogenic capacities.
Adrenal Insufficiency
Impairment of AVP regulation in 17alpha-hydroxylase deficiency, a unique form of adrenal insufficiency.
Adrenal Insufficiency
Novel mutation in cytochrome P450c17 causes complete combined 17alpha-hydroxylase/17,20-lyase deficiency.
Adrenal Insufficiency
Pubertal Presentation in Seven Patients with Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency.
Adrenocortical Adenoma
COUP-TFI expression in human adrenocortical adenomas: possible role in steroidogenesis.
Adrenocortical Adenoma
Expression profiles of COUP-TF, DAX-1, and SF-1 in the human adrenal gland and adrenocortical tumors: possible implications in steroidogenesis.
Adrenocortical Adenoma
Immunohistochemical study of cytochrome b5 in human adrenal gland and in adrenocortical adenomas from patients with Cushing's syndrome.
Adrenocortical Adenoma
Mechanism of dissociation of cortisol and adrenal androgen secretion after removal of adrenocortical adenoma in patients with Cushing's syndrome.
Adrenocortical Adenoma
Synaptophysin immunoreactivity in adrenocortical adenomas: a correlation between synaptophysin and CYP17A1 expression.
Adrenocortical Adenoma
[Nuclear receptors in the pathophysiology of endocrine tumors]
Adrenocortical Carcinoma
Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells.
Adrenocortical Carcinoma
Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line.
Adrenocortical Carcinoma
Expression of activin/inhibin signaling components in the human adrenal gland and the effects of activins and inhibins on adrenocortical steroidogenesis and apoptosis.
Adrenocortical Carcinoma
In vitro effects of brominated flame retardants and metabolites on CYP17 catalytic activity: a novel mechanism of action?
Adrenocortical Carcinoma
Inhibition of human placental aromatase activity by hydroxylated polybrominated diphenyl ethers (OH-PBDEs).
Adrenocortical Carcinoma
The Effect of Soy Isoflavones on Steroid Metabolism.
Alkalosis
A novel compound heterozygous mutation in the CYP17A1 gene in a patient with 17?-hydroxylase/17,20-lyase deficiency.
Alkalosis
P450C17 (CYP17) Deficiency in Native Mexican Patient with a Novel Mutation.
Alopecia
Female pattern hair loss in a patient with 17alpha-hydroxylase deficiency.
Alopecia
Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17.
Alzheimer Disease
Association between CYP17A1 rs3824755 and rs743572 gene polymorphisms and Alzheimer's disease in the Chinese Han population.
Alzheimer Disease
Variants in CYP17 and CYP19 cytochrome P450 genes are associated with onset of Alzheimer's disease in women with down syndrome.
Androgen-Insensitivity Syndrome
A case of 17alpha-hydroxylase deficiency with symptoms mimicking testicular feminization.
Antley-Bixler Syndrome Phenotype
Abnormal steroidogenesis in three patients with Antley-Bixler syndrome: apparent decreased activity of 17alpha-hydroxylase, 17,20-lyase and 21-hydroxylase.
Antley-Bixler Syndrome Phenotype
Combined homozygous 21 hydroxylase with heterozygous P450 oxidoreductase mutation in a Saudi boy presented with hypertension.
Antley-Bixler Syndrome Phenotype
Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients.
Antley-Bixler Syndrome Phenotype
Targeted gene panel sequencing for molecular diagnosis of congenital adrenal hyperplasia.
aromatase deficiency
Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic.
Arteriosclerosis
The importance of being dehydroepiandrosterone sulfate (in the blood of primates): a longer and healthier life?
Arthritis
17alpha-hydroxylase/C17-20 lyase cytochrome P450 mRNA expressions and enzyme activities during the development of arthritis in collagen-induced arthritis mice.
Arthritis, Rheumatoid
Association of CYP17 gene polymorphism and rheumatoid arthritis in Chinese patients in central Taiwan.
Arthritis, Rheumatoid
CYP17 polymorphisms and androgen levels in postmenopausal patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Possible association of CYP17 gene polymorphisms with the onset of rheumatoid arthritis.
Atherosclerosis
CYP17A1 deficient XY mice display susceptibility to atherosclerosis, altered lipidomic profile and atypical sex development.
Biliary Tract Neoplasms
CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China.
Breast Cyst
MspA1 polymorphism of the CYP17 gene in breast cysts.
Breast Diseases
Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women.
Breast Neoplasms
A polymorphism in CYP17 and endometrial cancer risk.
Breast Neoplasms
A polymorphism in the CYP17 gene increases the risk of breast cancer.
Breast Neoplasms
A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.
Breast Neoplasms
A protein-truncating mutation in CYP17A1 in three sisters with early-onset breast cancer.
Breast Neoplasms
Analysis of CYP17, CYP19 and CYP1A1 Gene Polymorphisms in Iranian Women with Breast Cancer.
Breast Neoplasms
Association between CYP17 gene polymorphism and risk of breast cancer in young women.
Breast Neoplasms
Association between CYP17 polymorphisms and the development of breast cancer.
Breast Neoplasms
Association between CYP17 T-34C rs743572 and breast cancer risk.
Breast Neoplasms
Association between the T27C polymorphism in the cytochrome P450 c17alpha (CYP17) gene and risk factors for breast cancer.
Breast Neoplasms
Association of a CYP17 Gene Polymorphism with Development of Breast Cancer in India.
Breast Neoplasms
Association of CYP17 genetic polymorphism with intra-tumoral estradiol concentrations but not with CYP17 messenger RNA levels in breast cancer tissue.
Breast Neoplasms
Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women.
Breast Neoplasms
Associations between the CYP17, CYPIB1, COMT and SHBG polymorphisms and serum sex hormones in post-menopausal breast cancer survivors.
Breast Neoplasms
Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway.
Breast Neoplasms
Breast cancer risk and polymorphisms in genes involved in metabolism of estrogens (CYP17, HSD17beta1, COMT and MnSOD): Possible protective role of MnSOD gene polymorphism Val/Ala and Ala/Ala in women that never breast fed.
Breast Neoplasms
Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility.
Breast Neoplasms
Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates.
Breast Neoplasms
Chemopreventive actions by enterolactone and 13 VIOXX-related lactone derivatives in H295R human adrenocortical carcinoma cells.
Breast Neoplasms
Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.
Breast Neoplasms
Current researches on breast cancer epidemiology in Korea.
Breast Neoplasms
CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility.
Breast Neoplasms
CYP17 (T34C), CYP19 (Trp39Arg), and FGFR2 (C906T) polymorphisms and the risk of breast cancer in south Indian women.
Breast Neoplasms
CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.
Breast Neoplasms
CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1.
Breast Neoplasms
CYP17 and breast cancer: no overall effect, but what about interactions?
Breast Neoplasms
CYP17 and SULT1A1 gene polymorphisms in Indian breast cancer.
Breast Neoplasms
CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients.
Breast Neoplasms
CYP17 gene polymorphism in relation to breast cancer risk: a case-control study.
Breast Neoplasms
CYP17 genetic polymorphism in endometrial cancer: are only steroids involved?
Breast Neoplasms
CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors.
Breast Neoplasms
CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study.
Breast Neoplasms
CYP17 genotype and breast cancer risk.
Breast Neoplasms
CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women.
Breast Neoplasms
CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans.
Breast Neoplasms
CYP17 MspA1 Gene Polymorphism and Breast Cancer Patients According to Age of Onset in Cancer Institute of Iran.
Breast Neoplasms
CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients.
Breast Neoplasms
CYP17 polymorphism in the groups of distinct breast cancer susceptibility: comparison of patients with the bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumor-free women.
Breast Neoplasms
CYP17 polymorphisms are associated with decreased risk of breast cancer in Chinese Han women: a case-control study.
Breast Neoplasms
CYP17 promoter polymorphism and breast cancer in Australian women under age forty years.
Breast Neoplasms
CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status.
Breast Neoplasms
CYP17, catechol-o-methyltransferase, and glutathione transferase M1 genetic polymorphisms, lifestyle factors, and breast cancer risk in women on prince edward island.
Breast Neoplasms
CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study.
Breast Neoplasms
Cyp17, urinary sex steroid levels and breast cancer risk in postmenopausal women.
Breast Neoplasms
Design and synthesis of functionalized piperazin-1yl-(E)-stilbenes as inhibitors of 17?-hydroxylase-C17,20-lyase (Cyp17).
Breast Neoplasms
Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.
Breast Neoplasms
DNA microarray-based analysis of single nucleotide polymorphisms may be useful for assessing the risks and benefits of hormone therapy.
Breast Neoplasms
Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project.
Breast Neoplasms
Estrogen-related genes and their contribution to racial differences in breast cancer risk.
Breast Neoplasms
Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk.
Breast Neoplasms
Evaluation of CYP17A1 and LEP Gene Polymorphisms in Breast Cancer.
Breast Neoplasms
Evaluation of Local CYP17A1 and CYP19A1 Expression Levels as Prognostic Factors in Postmenopausal Invasive Ductal Breast Cancer Cases.
Breast Neoplasms
Factors influencing the association between CYP17 T34C polymorphism and the risk of breast cancer: meta-regression and subgroup analysis.
Breast Neoplasms
Genetic Polymorphism CYP17 rs2486758 and Metabolic Risk Factors Predict Daily Salivary 17?-Estradiol Concentration in Healthy Premenopausal Norwegian Women. The EBBA-I Study.
Breast Neoplasms
Genetic polymorphism in CYP17 and breast cancer risk in Japanese women.
Breast Neoplasms
Genetic polymorphism of CYP17 and breast cancer risk in Korean women.
Breast Neoplasms
Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes.
Breast Neoplasms
Genetic polymorphisms of ESR1, ESR2, CYP17A1, and CYP19A1 and the risk of breast cancer: a case control study from North India.
Breast Neoplasms
Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.
Breast Neoplasms
Genetic Variations, Exposure to Persistent Organic Pollutants and Breast Cancer Risk: A Greenlandic Case-Control Study.
Breast Neoplasms
Genomic Profiling of the Steroidogenic Acute Regulatory Protein in Breast Cancer: In Silico Assessments and a Mechanistic Perspective.
Breast Neoplasms
HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore.
Breast Neoplasms
Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls.
Breast Neoplasms
Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism.
Breast Neoplasms
Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma.
Breast Neoplasms
No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer.
Breast Neoplasms
No association between CYP17 T-34C polymorphism and breast cancer risk: a meta-analysis involving 58,814 subjects.
Breast Neoplasms
No association of the 5' promoter region polymorphism of CYP17 with breast cancer risk in Japan.
Breast Neoplasms
Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.
Breast Neoplasms
Polymorphism in xenobiotic and estrogen metabolizing genes, exposure to perfluorinated compounds and subsequent breast cancer risk: A nested case-control study in the Danish National Birth Cohort.
Breast Neoplasms
Polymorphisms associated with circulating sex hormone levels in postmenopausal women.
Breast Neoplasms
Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women.
Breast Neoplasms
Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study.
Breast Neoplasms
Possible Risk Modification by Polymorphisms of Estrogen Metabolizing Genes in Familial Breast Cancer Susceptibility in an Indian Population.
Breast Neoplasms
Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism.
Breast Neoplasms
Re: CYP17 promoter polymorphism and breast cancer in Australian women under age forty years.
Breast Neoplasms
Regressive logistic and proportional hazards disease models for within-family analyses of measured genotypes, with application to a CYP17 polymorphism and breast cancer.
Breast Neoplasms
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
Breast Neoplasms
Steroid metabolism gene CYP17 polymorphism and the development of breast cancer.
Breast Neoplasms
Steroid metabolism gene polymorphisms and their implications on breast and ovarian cancer prognosis.
Breast Neoplasms
Steroidogenic cytochrome P450 17A1 structure and function.
Breast Neoplasms
Structures of human steroidogenic cytochrome P450 17A1 with substrates.
Breast Neoplasms
The CYP17 and CYP19 gene single nucleotide polymorphism in women with sporadic breast cancer.
Breast Neoplasms
The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.
Breast Neoplasms
The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.
Breast Neoplasms
The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.
Breast Neoplasms
The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in women.
Breast Neoplasms
Urinary bisphenol A and its interaction with CYP17A1 rs743572 are associated with breast cancer risk.
Breast Neoplasms
Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study.
Breast Neoplasms
[Association of polymorphism of genetic markers of CYP19 and CYP17 with sporadic breast cancer]
Breast Neoplasms
[Genetic polymorphism and variability of steroid hormone metabolism: connection with risk of developing breast neoplasms]
Breast Neoplasms
[Relation between single nucleotide polymorphism in estrogen-metabolizing genes COMT, CYP17 and breast cancer risk among Chinese women]
Breast Neoplasms
[Relationship between estrogen-biosynthesis gene (CYP17, CYP19, HSD17beta1) polymorphisms and breast cancer]
Breast Neoplasms
[Study on the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) and susceptibility to breast cancer in Chinese women]
Breast Neoplasms, Male
A polymorphism in the CYP17 gene is associated with male breast cancer.
Breast Neoplasms, Male
CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status.
Breast Neoplasms, Male
Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk.
Breast Neoplasms, Male
[Male breast cancer - history, epidemiolgy, genetic and histopathology.]
Carcinogenesis
Association between CYP17 gene polymorphism and risk of breast cancer in young women.
Carcinogenesis
CYP17 polymorphism (rs743572) is associated with increased risk of gallbladder cancer in tobacco users.
Carcinogenesis
CYP17A1 T-34C polymorphism is not associated with endometrial cancer risk.
Carcinogenesis
Cytochrome P450 17 (CYP17) Is Involved in Endometrial Cancinogenesis Through Apoptosis and Invasion Pathways.
Carcinoma
Aminoglutethimide and ketoconazole: historical perspectives and future prospects.
Carcinoma
Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Carcinoma
Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens.
Carcinoma
Comparison of [17(20)E]-21-Norpregnene oxazolinyl and benzoxazolyl derivatives as inhibitors of CYP17A1 activity and prostate carcinoma cells growth.
Carcinoma
Corrigendum to "Comparison of [17(20)E]-21-Norpregnene oxazolinyl and benzoxazolyl derivatives as inhibitors of CYP17A1 activity and prostate carcinoma cells growth" [Steroids 129 (2018) 24-34].
Carcinoma
CYP17 genetic polymorphism in patients with endometrial hyperplasia and cancer.
Carcinoma
CYP17A1 and Androgen-Receptor Expression in Prostate Carcinoma Tissues and Cancer Cell Lines.
Carcinoma
Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms.
Carcinoma
Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders.
Carcinoma
New azole derivatives of [17(20)E]-21-norpregnene: Synthesis and inhibition of prostate carcinoma cell growth.
Carcinoma
Polymorphisms of metabolic enzyme genes, living habits and prostate cancer susceptibility.
Carcinoma
Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
Carcinoma
Regulation of P450c17 expression in the early embryo depends on GATA factors.
Carcinoma
Role of the Mevalonate Pathway in Adrenocortical Tumorigenesis.
Carcinoma
The Role of Fluorine Substitution in Biphenyl Methylene Imidazole-Type CYP17 Inhibitors for the Treatment of Prostate Carcinoma.
Carcinoma, Ovarian Epithelial
Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer.
Cardiomegaly
A Single Nucleotide Polymorphism near the CYP17A1 Gene Is Associated with Left Ventricular Mass in Hypertensive Patients under Pharmacotherapy.
Cardiovascular Diseases
Assessment of the potential of polyphenols as a CYP17 inhibitor free of adverse corticosteroid elevation.
Cholera
Activity of the CYP17 promoter in bovine adrenocortical cells before and after phenotypic switching.
Cholera
Interaction of phorbol ester and adrenocorticotropin in the regulation of steroidogenic P450 genes in human fetal and adult adrenal cell cultures.
Cholestasis
Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis.
Cholestasis, Intrahepatic
[Association between polymorphisms of CYP17 and CYP3A4 genes and intrahepatic cholestasis of pregnancy in Chengdu]
Colonic Neoplasms
Cytochrome P450 17A1 and catechol O-methyltransferase polymorphisms and age at Lynch syndrome colon cancer onset in Newfoundland.
Colorectal Neoplasms
Cytochrome P450 17A1 and catechol O-methyltransferase polymorphisms and age at Lynch syndrome colon cancer onset in Newfoundland.
Colorectal Neoplasms
Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk.
Colorectal Neoplasms, Hereditary Nonpolyposis
Cytochrome P450 17A1 and catechol O-methyltransferase polymorphisms and age at Lynch syndrome colon cancer onset in Newfoundland.
Congenital Abnormalities
A 28-day oral dose toxicity study enhanced to detect endocrine effects of a purified technical pentabromodiphenyl ether (pentaBDE) mixture in Wistar rats.
Coronary Artery Disease
Are the T/C polymorphism of the CYP17 gene and the tetranucleotide repeat (TTTA) polymorphism of the CYP19 gene genetic markers for premature coronary artery disease in Caucasians?
Coronary Artery Disease
CYP17A1 deficient XY mice display susceptibility to atherosclerosis, altered lipidomic profile and atypical sex development.
Coronary Artery Disease
Genetic Variant in the CYP17 Gene and Risk of Premature Coronary Artery Disease.
Coronary Artery Disease
Haplotype analyses of CYP17A1 genetic polymorphisms and coronary artery disease in a Uygur population.
Coronary Artery Disease
Relationship between CYP17A1 genetic polymorphism and coronary artery disease in a Chinese Han population.
Coronary Disease
CYP17A1 Polymorphisms Are Linked to the Risk of Coronary Heart Disease in a Case-Control Study.
Cryptorchidism
Altered expression of CYP17A1 and CYP19A1 in undescended testes of dogs with unilateral cryptorchidism.
Cryptorchidism
Association of variants in genes involved in environmental chemical metabolism and risk of cryptorchidism and hypospadias.
Cryptorchidism
Expression of anti-Müllerian hormone, CDKN1B, connexin 43, androgen receptor and steroidogenic enzymes in the equine cryptorchid testis.
Cushing Syndrome
11Beta-Hydroxylase Deficiency and Other Syndromes of Mineralocorticoid Excess as a Rare Cause of Endocrine Hypertension.
Cushing Syndrome
A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome.
Cushing Syndrome
Design and synthesis of functionalized piperazin-1yl-(E)-stilbenes as inhibitors of 17?-hydroxylase-C17,20-lyase (Cyp17).
Cushing Syndrome
Editorial comment from Dr Fang to increased expression of CYP17 and CYP11B1 in subclinical Cushing's syndrome due to adrenal adenomas.
Cushing Syndrome
Editorial comment from Dr Ishidoya to increased expression of CYP17 and CYP11B1 in subclinical Cushing's syndrome due to adrenal adenomas.
Cushing Syndrome
Expression profiles of COUP-TF, DAX-1, and SF-1 in the human adrenal gland and adrenocortical tumors: possible implications in steroidogenesis.
Cushing Syndrome
Hypertension and adrenal disorders.
Cushing Syndrome
Immunohistochemical study of cytochrome b5 in human adrenal gland and in adrenocortical adenomas from patients with Cushing's syndrome.
Cushing Syndrome
In vitro release of aldosterone and cortisol in human adrenal adenomas correlates to mRNA expression of steroidogenic enzymes for genes CYP11B2 and CYP17.
Cushing Syndrome
Increased expression of CYP17 and CYP11B1 in subclinical Cushing's syndrome due to adrenal adenomas.
Cushing Syndrome
New aspects on primary aldosteronism.
Cushing Syndrome
Renin-Independent hypermineralocorticoidism.
Cushing Syndrome
Simultaneous determination of plasma 11-deoxycorticosterone, 18-hydroxy-11-deoxycorticosterone, and aldosterone in man.
Cushing Syndrome
Steroidogenic cytochrome P450 17A1 structure and function.
Cysts
Cellular localization of androgen synthesis in equine granulosa-theca cell tumors: Immunohistochemical expression of 17alpha-hydroxylase/17,20-lyase cytochrome P450.
Cysts
Changes in the expression of cytochrome P450c17 associated with ovarian cystic follicles. An immunocytochemical and enzymatic analysis of porcine ovaries.
Cysts
Supraphysiological leptin levels shift the profile of steroidogenesis in porcine ovarian follicles toward progesterone and testosterone secretion through increased expressions of CYP11A1 and 17?-HSD: a tissue culture approach.
Demyelinating Diseases
Suppressed oligodendrocyte steroidogenesis in multiple sclerosis: Implications for regulation of neuroinflammation.
Diabetes Mellitus, Type 1
3beta-hydroxysteroid dehydrogenase autoantibodies are rare in premature ovarian failure.
Diabetes Mellitus, Type 2
[Ginkgo biloba extract enhances testosterone synthesis of Leydig cells in type 2 diabetic rats]
Disorder of Sex Development, 46,XY
17alpha-hydroxylase/17,20-Lyase deficiency due to novel compound heterozygote mutations: treatment for tall stature in a female with male pseudohermaphroditism and spontaneous puberty in her affected sister.
Disorder of Sex Development, 46,XY
A novel compound heterozygous mutation in the CYP17A1 gene in a patient with 17?-hydroxylase/17,20-lyase deficiency.
Disorder of Sex Development, 46,XY
A novel compound heterozygous mutation of K494_V495 deletion plus R496L and D487_F489 deletion in extreme C-terminus of cytochrome P450c17 causes 17alpha-hydroxylase deficiency.
Disorder of Sex Development, 46,XY
Clinical characteristics and mutation analysis of two Chinese children with 17a-hydroxylase/17,20-lyase deficiency.
Disorder of Sex Development, 46,XY
P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping.
Disorder of Sex Development, 46,XY
Production of male pseudohermaphroditism in rats by two new inhibitors of steroid 17alpha-hydroxylase and C 17-20 lyase.
Disorder of Sex Development, 46,XY
Two novel heterozygous mutations in the CYP17A1 gene in a Chinese patient with 17?-hydroxylase 17,20-lyase deficiency.
Disorders of Sex Development
Ambiguous genitalia due to partial activity of cytochromes P450c17 and P450c21.
Disorders of Sex Development
Clinical, genetic and functional characteristics of three novel CYP17A1 mutations causing combined 17alpha-hydroxylase/17,20-lyase deficiency.
Disorders of Sex Development
Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P.
Disorders of Sex Development
Phenotype-genotype correlation in eight Chinese 17alpha-hydroxylase/17,20 lyase-deficiency patients with five novel mutations of CYP17A1 gene.
Down Syndrome
Variants in CYP17 and CYP19 cytochrome P450 genes are associated with onset of Alzheimer's disease in women with down syndrome.
Dyskinesias
Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia.
Encephalomyelitis
Suppressed oligodendrocyte steroidogenesis in multiple sclerosis: Implications for regulation of neuroinflammation.
Encephalomyelitis, Autoimmune, Experimental
Suppressed oligodendrocyte steroidogenesis in multiple sclerosis: Implications for regulation of neuroinflammation.
Endometrial Hyperplasia
CYP17 genetic polymorphism in patients with endometrial hyperplasia and cancer.
Endometrial Neoplasms
A polymorphism in CYP17 and endometrial cancer risk.
Endometrial Neoplasms
CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity.
Endometrial Neoplasms
CYP17 genetic polymorphism in endometrial cancer: are only steroids involved?
Endometrial Neoplasms
CYP17 genetic polymorphism in patients with endometrial hyperplasia and cancer.
Endometrial Neoplasms
CYP17A1 T-34C polymorphism is not associated with endometrial cancer risk.
Endometrial Neoplasms
CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility.
Endometrial Neoplasms
Cytochrome P450 17 (CYP17) Is Involved in Endometrial Cancinogenesis Through Apoptosis and Invasion Pathways.
Endometrial Neoplasms
Expression of enzyme associated with steroid hormone synthesis and local production of steroid hormone in endometrial carcinoma cells.
Endometrial Neoplasms
Expression of messenger ribonucleic acid encoding steroidogenic enzymes in postmenopausal ovaries.
Endometrial Neoplasms
Genetic variation in CYP17 and endometrial cancer risk.
Endometrial Neoplasms
Genetic variation in CYP17A1 and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California.
Endometrial Neoplasms
Genetic variation of the CYP17 and susceptibility to endometrial cancer: a meta-analysis.
Endometrial Neoplasms
Hormonal imbalance in two types of endometrial cancer and genetic polymorphism of steroidogenic enzymes.
Endometrial Neoplasms
Prostaglandin E2 triggers cytochrome P450 17? hydroxylase overexpression via signal transducer and activator of transcription 3 phosphorylation and promotes invasion in endometrial cancer.
Endometrial Neoplasms
Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype.
Endometrial Neoplasms
The polymorphisms of the CYP17 and CYP19 genes in endometrial cancer patients.
Endometrial Neoplasms
The T/C polymorphism of the CYP17 gene and G/A polymorphism of the CYP19 gene in endometrial cancer.
Endometrial Neoplasms
Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review.
Endometrial Neoplasms
Variants in hormone biosynthesis genes and risk of endometrial cancer.
Endometrial Neoplasms
[A case-control study on genetic polymorphism of CYP17 MspA(1)I and its association with endometrial cancer risk]
Endometrial Neoplasms
[Genetic polymorphism of steroid 17 alpha-hydroxylase/17,20-lyase (CYP17) and hyperinsulinemia in endometrial carcinoma]
Endometrial Neoplasms
[Genetic polymorphism of steroidogenic enzymes and steroid receptor level in tumors of the reproductive system]
Endometriosis
Association of endometriosis risk and genetic polymorphisms involving biosynthesis of sex steroids and their receptors: an updating meta-analysis.
Endometriosis
Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women.
Endometriosis
Association study between CYP17 gene polymorphism and endometriosis risk: A meta-analysis.
Endometriosis
Combined Effect of the PGR +331C?>?T, CYP17A1 -34A?>?G and CYP19A1 1531G?>?A Polymorphisms on the Risk of Developing Endometriosis.
Endometriosis
Common Variation in the CYP17A1 and IFIT1 Genes on Chromosome 10 Does Not Contribute to the Risk of Endometriosis.
Endometriosis
Common variation of the CYP17 gene in Iraqi women with endometriosis disease.
Endometriosis
Cross-disorder analysis of endometriosis and its comorbid diseases reveals shared genes and molecular pathways and proposes putative biomarkers of endometriosis.
Endometriosis
CYP17 and CYP19 gene polymorphisms in women affected with endometriosis.
Endometriosis
CYP17 and CYP2C19 gene polymorphisms in patients with endometriosis.
Endometriosis
CYP17, CYP1A1 and COMT polymorphisms and the risk of adenomyosis and endometriosis in Taiwanese women.
Endometriosis
CYP17A1 rs743572 polymorphism might contribute to endometriosis susceptibility: evidences from a case-control study.
Endometriosis
Cytochrome P450c17alpha 5'-untranslated region *T/C polymorphism in endometriosis.
Endometriosis
Estrogen receptor alpha dinucleotide repeat and cytochrome P450c17alpha gene polymorphisms are associated with susceptibility to endometriosis.
Endometriosis
Lack of association between endometriosis and the CYP17 MspA1 polymorphism in UK and Japanese populations.
Endometriosis
Polymorphic variants of CYP17 and CYP19A and risk of infertility in endometriosis.
Endometriosis
[Association of single nucleotide polymorphism in CYP17 and ER? genes with endometriosis risk in southern Chinese women].
Essential Hypertension
Association of CYP17A1 Genetic Polymorphisms and Susceptibility to Essential Hypertension in the Southwest Han Chinese Population.
Essential Hypertension
Relationship between CYP17A1 Genetic Polymorphism and Essential Hypertension in a Chinese Population.
Fetal Growth Retardation
A polymorphism in the CYP17 gene and intrauterine fetal growth restriction.
Fetal Growth Retardation
Functional maternal catechol-O-methyltransferase polymorphism and fetal growth restriction.
Fetal Growth Retardation
Genetic factors in fetal growth restriction and miscarriage.
Fetal Growth Retardation
Genetic polymorphism of catechol-O-methyltransferase and cytochrome P450c17? in preeclampsia.
Fetal Growth Retardation
Prenatal alcohol exposure, CYP17 gene polymorphisms and fetal growth restriction.
Fibroadenoma
Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women.
Fibroadenoma
Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma.
Follicular Cyst
Dominant bovine ovarian follicular cysts express increased levels of messenger RNAs for luteinizing hormone receptor and 3 beta-hydroxysteroid dehydrogenase delta(4),delta(5) isomerase compared to normal dominant follicles.
Gallbladder Diseases
CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China.
Gallbladder Neoplasms
CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China.
Gallbladder Neoplasms
CYP17 polymorphism (rs743572) is associated with increased risk of gallbladder cancer in tobacco users.
Gallstones
CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China.
Genetic Diseases, Inborn
A new compound heterozygous mutation (W17X, 436 + 5G --> T) in the cytochrome P450c17 gene causes 17 alpha-hydroxylase/17,20-lyase deficiency.
Genetic Diseases, Inborn
Clinical and Genetic Characteristics of 17 ?-Hydroxylase/17, 20-Lyase Deficiency: c.985_987delTACinsAA Mutation of CYP17A1 Prevalent in the Chinese Han Population.
Genetic Diseases, Inborn
Point mutation of Arg440 to His in cytochrome P450c17 causes severe 17 alpha-hydroxylase deficiency.
Glioblastoma
CYP17A1 Maintains the Survival of Glioblastomas by Regulating SAR1-Mediated Endoplasmic Reticulum Health and Redox Homeostasis.
Glioblastoma
Dehydroepiandrosterone Induces Temozolomide Resistance Through Modulating Phosphorylation and Acetylation of Sp1 in Glioblastoma.
Glioblastoma
Steroidogenic cytochrome P450 17A1 structure and function.
Glioma
Effects of lentivirus-mediated CYP17A1 gene silencing on the biological activity of glioma.
Glioma
Relationship between CYP17A1-Mediated DNA Demethylation and Proliferation, Invasion and Metastasis of Glioma Cells.
Glioma
Upregulation of CYP17A1 by Sp1-mediated DNA demethylation confers temozolomide resistance through DHEA-mediated protection in glioma.
Gonadoblastoma
A novel point mutation in P450c17 (CYP17) causing combined 17alpha-hydroxylase/17,20-lyase deficiency.
Gynecomastia
CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding.
Hamartoma Syndrome, Multiple
Epidemiology of male breast cancer.
Heart Diseases
Abiraterone Acetate: In Metastatic Castration-Resistant Prostate Cancer.
Heart Diseases
Abiraterone acetate: in metastatic castration-resistant prostate cancer.
Hemochromatosis
[Male breast cancer - history, epidemiolgy, genetic and histopathology.]
Hepatitis
Target proteins in human autoimmunity: cytochromes P450 and UDP- glucuronosyltransferases.
Hepatitis B
Transcriptome Analysis of WHV/c-myc Transgenic Mice Implicates Cytochrome P450 Enzyme 17A1 as a Promising Biomarker for Hepatocellular Carcinoma.
Herpes Zoster
3?HSD and CYB5A double positive adrenocortical cells during adrenal development/aging.
Herpes Zoster
Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome.
Herpes Zoster
Adrenal steroidogenesis following prenatal dexamethasone exposure in the spiny mouse.
Herpes Zoster
Adrenocortical cytochrome b5 expression during fetal development of the rhesus macaque.
Herpes Zoster
Aldosterone-Producing Adenomas: Histopathology-Genotype Correlation and Identification of a Novel CACNA1D Mutation.
Herpes Zoster
Alteration of the steroidogenesis in boys with autism spectrum disorders.
Herpes Zoster
Androgen synthesis in adrenarche.
Herpes Zoster
Autoantibodies to cytochrome P450 enzymes P450scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison's disease.
Herpes Zoster
Biochemical, Histopathological, and Genetic Characterization of Posture-Responsive and Unresponsive APAs.
Herpes Zoster
Colocalization of P450c17 and cytochrome b5 in androgen-synthesizing tissues of the human.
Herpes Zoster
Cytochrome b(5) modulation of 17{alpha} hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis.
Herpes Zoster
Development of adrenal cortical zonation and expression of key elements of adrenal androgen production in the chimpanzee (Pan troglodytes) from birth to adulthood.
Herpes Zoster
Developmental changes in steroidogenic enzymes in human postnatal adrenal cortex: immunohistochemical studies.
Herpes Zoster
Functional aromatase expression in porcine adrenal gland and testis.
Herpes Zoster
Genetic and Histopathologic Inter-Tumor Heterogeneity in Primary Aldosteronism.
Herpes Zoster
Immunohistochemical localisation of steroidogenic enzymes and phenylethanolamine-N-methyl-transferase (PNMT) in the adrenal gland of the fetal and newborn foal.
Herpes Zoster
Immunolocalization and biochemical determination of cytochrome P450C17 in adrenals of hamsters treated with ACTH.
Herpes Zoster
Long-term hypoxia increases endothelial nitric oxide synthase expression in the ovine fetal adrenal.
Herpes Zoster
Maturational changes in CYP2D16 expression and xenobiotic metabolism in adrenal glands from male and female guinea pigs.
Herpes Zoster
New aspects on primary aldosteronism.
Herpes Zoster
Ontogeny of angiotensin II type 1 receptor and cytochrome P450(c11) in the sheep adrenal gland.
Herpes Zoster
Ontogeny of the adrenal gland in the spiny mouse, with particular reference to production of the steroids cortisol and dehydroepiandrosterone.
Herpes Zoster
Primary aldosteronism associated with subclinical Cushing syndrome.
Herpes Zoster
Protein kinase A, protein kinase C, and Ca(2+)-regulated expression of 21-hydroxylase cytochrome P450 in H295R human adrenocortical cells.
Herpes Zoster
Protein kinase C-induced activin A switches adrenocortical steroidogenesis to aldosterone by suppressing CYP17A1 expression.
Herpes Zoster
Role of cytochrome b5 in the modulation of the enzymatic activities of cytochrome P450 17?-hydroxylase/17,20-lyase (P450 17A1).
Herpes Zoster
Steroidogenic enzymes.
Herpes Zoster
The feto-placental unit, and potential roles of dehydroepiandrosterone (DHEA) in prenatal and postnatal brain development: A re-examination using the spiny mouse.
Herpes Zoster
The importance of being dehydroepiandrosterone sulfate (in the blood of primates): a longer and healthier life?
Herpes Zoster
The molecular basis of premature adrenarche: an hypothesis.
Herpes Zoster
The primate adrenal zona reticularis is defined by expression of cytochrome b5, 17alpha-hydroxylase/17,20-lyase cytochrome P450 (P450c17) and NADPH-cytochrome P450 reductase (reductase) but not 3beta-hydroxysteroid dehydrogenase/delta5-4 isomerase (3beta-HSD).
Herpes Zoster
Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling.
Hirsutism
The human 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) gene cluster on chromosome 1p13 contains a presumptive pseudogene; 3 beta-HSD and CYP17 do not segregate with dominantly inherited hirsutism.
Hyperaldosteronism
11Beta-Hydroxylase Deficiency and Other Syndromes of Mineralocorticoid Excess as a Rare Cause of Endocrine Hypertension.
Hyperaldosteronism
A Dispensable Role for P450(scc) in the Overproduction of Aldosterone in Aldosterone-Producing Adenoma and Idiopathic Hyperaldosteronism in Patients with Primary Aldosteronism.
Hyperaldosteronism
A potential role for CPY17 as a parameter in differentiation between aldosterone-producing adenoma and nodular hyperplasia in patients with hyperaldosteronism.
Hyperaldosteronism
Adrenocortical factors in hypertension. I. Significance of 18-hydroxy-11-deoxycorticosterone.
Hyperaldosteronism
Aldosterone-producing adenoma with prolonged amelioration by dexamethasone.
Hyperaldosteronism
Hypertension and adrenal disorders.
Hyperaldosteronism
Mutation of cytochrome P-45017 alpha gene (CYP17) in a Japanese patient previously reported as having glucocorticoid-responsive hyperaldosteronism: with a review of Japanese patients with mutations of CYP17.
Hyperaldosteronism
The role of adrenal steroidogenesis in arterial hypertension.
Hyperalgesia
Inhibition of cytochrome P450c17 reduces spinal astrocyte activation in a mouse model of neuropathic pain via regulation of p38 MAPK phosphorylation.
Hyperalgesia
Spinal cytochrome P450c17 plays a key role in the development of neuropathic mechanical allodynia: Involvement of astrocyte sigma-1 receptors.
Hyperalgesia
Spinal Interleukin-1? Inhibits Astrocyte Cytochrome P450c17 Expression Which Controls the Development of Mechanical Allodynia in a Mouse Model of Neuropathic Pain.
Hyperandrogenism
17 alpha-hydroxylase/17,20-lyase dysregulation is not caused by mutations in the coding regions of CYP17.
Hyperandrogenism
Adrenal androgen excess in women: lack of a role for 17-hydroxylase and 17,20-lyase dysregulation.
Hyperandrogenism
CYP17 gene polymorphic sequence variation is associated with hyperandrogenism in Kashmiri women with polycystic ovarian syndrome.
Hyperandrogenism
Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
Hyperandrogenism
Enzymatic activities of P450c17 stably expressed in fibroblasts from patients with the polycystic ovary syndrome.
Hyperandrogenism
Hypersecretion of androgens by polycystic ovaries: the role of genetic factors in the regulation of cytochrome P450c17 alpha.
Hyperandrogenism
Increased expression of P450scc and CYP17 in development of endogenous hyperandrogenism in a rat model of PCOS.
Hyperandrogenism
Involvement of growth factors in the pathophysiology of polycystic ovary syndrome.
Hyperandrogenism
Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens.
Hyperandrogenism
Nonhuman primates as models for human adrenal androgen production: Function and dysfunction.
Hyperandrogenism
Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
Hyperandrogenism
Ovarian suppression with triptorelin and adrenal stimulation with adrenocorticotropin in functional hyperadrogenism: role of adrenal and ovarian cytochrome P450c17 alpha.
Hyperandrogenism
Oxidative stress increases the 17,20-lyase-catalyzing activity of adrenal P450c17 through p38? in the development of hyperandrogenism.
Hyperandrogenism
Pathophysiology of ovarian steroid secretion in polycystic ovary syndrome.
Hyperandrogenism
Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome.
Hyperandrogenism
The regulation of human p450c17 activity: relationship to premature adrenarche, insulin resistance and the polycystic ovary syndrome.
Hyperandrogenism
[Polymorphism in CYP11alpha and CYP17 genes and the etiology of hyperandrogenism in patients with polycystic ovary syndrome]
Hypercholesterolemia
The CYP17A1 gene polymorphisms are associated with hypercholesterolemia in Han Chinese.
Hyperglycemia
Obesity-induced excess of 17-hydroxyprogesterone promotes hyperglycemia through activation of glucocorticoid receptor.
Hyperinsulinism
17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss.
Hyperinsulinism
Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
Hyperinsulinism
Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity.
Hyperinsulinism
Lack of relationship between 17-hydroxyprogesterone response to buserelin testing and hyperinsulinemia in polycystic ovary syndrome.
Hyperinsulinism
Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens.
Hyperinsulinism
[Insulin sensitivity and polycystic ovarian syndrome]
Hyperinsulinism
[Polycystic ovary and diazoxide. In vivo study]
Hypertension
17-Hydroxyprogesterone deficiency as a cause of sexual infantilism and arterial hypertension: laboratory and molecular diagnosis--a case report.
Hypertension
17?-Hydroxylase Deficiency Diagnosed in Early Infancy Caused by a Novel Mutation of the CYP17A1 Gene.
Hypertension
A compound heterozygous mutation in the CYP17 (17alpha-hydroxylase/17,20-lyase) gene in a Chinese subject with congenital adrenal hyperplasia.
Hypertension
A novel compound heterozygous mutation in the CYP17 (P450 17alpha-hydroxylase) gene leading to 17alpha-hydroxylase/17,20-lyase deficiency.
Hypertension
A novel compound heterozygous mutation in the CYP17A1 gene in a patient with 17?-hydroxylase/17,20-lyase deficiency.
Hypertension
A novel compound heterozygous mutation of K494_V495 deletion plus R496L and D487_F489 deletion in extreme C-terminus of cytochrome P450c17 causes 17alpha-hydroxylase deficiency.
Hypertension
A rare cause of delayed puberty in two cases with 46,XX and 46,XY karyotype: 17 ?-hydroxylase deficiency due to a novel variant in CYP17A1 gene.
Hypertension
A rare intronic mutation in the splice acceptor site of the CYP17A1 gene in a patient with 17?-hydroxylase/17,20-lyase deficiency.
Hypertension
A review of the literature on common CYP17A1 mutations in adults with 17-hydroxylase/17,20-lyase deficiency, a case series of such mutations among Koreans and functional characteristics of a novel mutation.
Hypertension
A sex-specific effect of the CYP17A1 SNP rs11191548 on blood pressure in Chinese children.
Hypertension
A Single Nucleotide Polymorphism near the CYP17A1 Gene Is Associated with Left Ventricular Mass in Hypertensive Patients under Pharmacotherapy.
Hypertension
A unique exonic splicing mutation in the CYP17A1 gene as the cause for steroid 17{alpha}-hydroxylase deficiency.
Hypertension
ACTH and Polymorphisms at Steroidogenic Loci as Determinants of Aldosterone Secretion and Blood Pressure.
Hypertension
Association of common variants in/near six genes (ATP2B1, CSK, MTHFR, CYP17A1, STK39 and FGF5) with blood pressure/hypertension risk in Chinese children.
Hypertension
Association of CYP17A1 Genetic Polymorphisms and Susceptibility to Essential Hypertension in the Southwest Han Chinese Population.
Hypertension
Associations of the hypertension-related single nucleotide polymorphism rs11191548 with high-density lipoprotein cholesterol and leptin in Chinese children.
Hypertension
Clinical characteristics and mutation analysis of two Chinese children with 17a-hydroxylase/17,20-lyase deficiency.
Hypertension
Clinical, hormonal, ovarian, and genetic aspects of 46,XX patients with congenital adrenal hyperplasia due to CYP17A1 defects.
Hypertension
Combined 17 alpha-hydroxylase/17,20-lyase deficiency due to a homozygous 25 BP duplication (NT 4157-4181) at exon 5 in the CYP17 resulting in a premature stop codon predicted by molecular modeling.
Hypertension
Combined 17?-hydroxylase/17,20-lyase deficiency due to p.R96W mutation in the CYP17 gene in a Brazilian patient.
Hypertension
Common Polymorphism rs11191548 Near the CYP17A1 Gene Is Associated With Hypertension and Systolic Blood Pressure in the Han Chinese Population.
Hypertension
Common variant rs11191548 near the CYP17A1 gene is associated with hypertension and the serum 25(OH) D levels in Han Chinese.
Hypertension
Common variants in or near FGF5, CYP17A1 and MTHFR genes are associated with blood pressure and hypertension in Chinese Hans.
Hypertension
Common variants in the ATP2B1 gene are associated with susceptibility to hypertension: the Japanese Millennium Genome Project.
Hypertension
CYP17A1 and Blood Pressure Reactivity to Stress in Adolescence.
Hypertension
CYP17A1 gene mutations and hypertension variations found in 46, XY females with combined 17?-hydroxylase/17, 20-lyase deficiency.
Hypertension
Disorders of androgen synthesis--from cholesterol to dehydroepiandrosterone.
Hypertension
Exploration of CYP21A2 and CYP17A1 polymorphisms and preeclampsia risk among Chinese Han population: a large-scale case-control study based on 5021 subjects.
Hypertension
Female phenotype with male karyotype: a clinical enigma.
Hypertension
Genetic aspects of congenital adrenal hyperplasia.
Hypertension
Genetic variations in CYP17A1, CACNB2 and PLEKHA7 are associated with blood pressure and/or hypertension in she ethnic minority of China.
Hypertension
Genome-wide association study of blood pressure and hypertension.
Hypertension
Hypertension and adrenal disorders.
Hypertension
Hypertension due to 17alpha-hydroxylase deficiency.
Hypertension
Identifying a novel mutation of CYP17A1 gene from five Chinese 17?-hydroxylase/17, 20-lyase deficiency patients.
Hypertension
Long term follow-up of a 46,XY phenotypic girl with 17alpha-hydroxylase deficiency treated with alternate-day dexamethasone.
Hypertension
Loss of Cytochrome P450 17A1 Protein Expression in a 17alpha-Hydroxylase/17,20-Lyase-Deficient 46,XY Female Caused by Two Novel Mutations in the CYP17A1 Gene.
Hypertension
New compound heterozygous mutation in the CYP17 gene in a 46,XY girl with 17 alpha-hydroxylase/17,20-lyase deficiency.
Hypertension
New, recurrent, and prevalent mutations: Clinical and molecular characterization of 26 Chinese patients with 17alpha-hydroxylase/17,20-lyase deficiency.
Hypertension
Novel mutation in cytochrome P450c17 causes complete combined 17alpha-hydroxylase/17,20-lyase deficiency.
Hypertension
Novel P450c17 mutation H373D causing combined 17alpha-hydroxylase/17,20-lyase deficiency.
Hypertension
P450C17 (CYP17) Deficiency in Native Mexican Patient with a Novel Mutation.
Hypertension
P450c17 Deficiency Caused by Compound Heterozygosity for Two Novel Mutations Presenting as Hypotension in Early Infancy.
Hypertension
P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping.
Hypertension
P450c17 deficiency: clinical and molecular characterization of six patients.
Hypertension
Phenotype-genotype correlation in eight Chinese 17alpha-hydroxylase/17,20 lyase-deficiency patients with five novel mutations of CYP17A1 gene.
Hypertension
Phenotypic variation in a Chinese family with 46,XY and 46,XX 17?-hydroxylase deficiency.
Hypertension
Quantitative and qualitative proteome characteristics extracted from in-depth integrated genomics and proteomics analysis.
Hypertension
Rare hypertension as a result of 17alpha-hydroxylase deficiency.
Hypertension
Recapitulation of four hypertension susceptibility genes (CSK, CYP17A1, MTHFR, and FGF5) in East Asians.
Hypertension
Recapitulation of two genomewide association studies on blood pressure and essential hypertension in the Korean population.
Hypertension
The CYP17A1 gene polymorphisms are associated with hypercholesterolemia in Han Chinese.
Hypertension
The genetics, pathophysiology, and management of human deficiencies of P450c17.
Hypertension
The relationship between the polymorphisms of the CYP17A1 gene and hypertension: A meta-analysis.
Hypertension
Two novel heterozygous mutations in the CYP17A1 gene in a Chinese patient with 17?-hydroxylase 17,20-lyase deficiency.
Hypertension
Two novel mutations found in a patient with 17alpha-hydroxylase enzyme deficiency.
Hypertension
Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency.
Hypertension
[Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
Hypoaldosteronism
Genetic analysis of the cytochrome P-450c17alpha (CYP17) and aldosterone synthase (CYP11B2) in Japanese patients with 17alpha-hydroxylase deficiency.
Hypogonadism
17?-HYDROXYLASE DEFICIENCY IS AN UNDERDIAGNOSED DISEASE: HIGH FREQUENCY OF MISDIAGNOSES IN A LARGE COHORT OF BRAZILIAN PATIENTS.
Hypogonadism
A novel compound heterozygous mutation in the CYP17A1 gene in a patient with 17?-hydroxylase/17,20-lyase deficiency.
Hypogonadism
A novel point mutation in P450c17 (CYP17) causing combined 17alpha-hydroxylase/17,20-lyase deficiency.
Hypogonadism
Clinical, hormonal, ovarian, and genetic aspects of 46,XX patients with congenital adrenal hyperplasia due to CYP17A1 defects.
Hypogonadism
Combined 17?-hydroxylase/17,20-lyase deficiency due to p.R96W mutation in the CYP17 gene in a Brazilian patient.
Hypogonadism
Hypertension due to 17alpha-hydroxylase deficiency.
Hypogonadism
P450C17 (CYP17) Deficiency in Native Mexican Patient with a Novel Mutation.
Hypokalemia
17-Hydroxyprogesterone deficiency as a cause of sexual infantilism and arterial hypertension: laboratory and molecular diagnosis--a case report.
Hypokalemia
17?-Hydroxylase Deficiency Diagnosed in Early Infancy Caused by a Novel Mutation of the CYP17A1 Gene.
Hypokalemia
A compound heterozygous mutation in the CYP17 (17alpha-hydroxylase/17,20-lyase) gene in a Chinese subject with congenital adrenal hyperplasia.
Hypokalemia
A novel compound heterozygous mutation in the CYP17A1 gene in a patient with 17?-hydroxylase/17,20-lyase deficiency.
Hypokalemia
A novel compound heterozygous mutation of K494_V495 deletion plus R496L and D487_F489 deletion in extreme C-terminus of cytochrome P450c17 causes 17alpha-hydroxylase deficiency.
Hypokalemia
A rare intronic mutation in the splice acceptor site of the CYP17A1 gene in a patient with 17?-hydroxylase/17,20-lyase deficiency.
Hypokalemia
A unique exonic splicing mutation in the CYP17A1 gene as the cause for steroid 17{alpha}-hydroxylase deficiency.
Hypokalemia
Clinical characteristics and mutation analysis of two Chinese children with 17a-hydroxylase/17,20-lyase deficiency.
Hypokalemia
Identifying a novel mutation of CYP17A1 gene from five Chinese 17?-hydroxylase/17, 20-lyase deficiency patients.
Hypokalemia
Impairment of AVP regulation in 17alpha-hydroxylase deficiency, a unique form of adrenal insufficiency.
Hypokalemia
P450c17 Deficiency Caused by Compound Heterozygosity for Two Novel Mutations Presenting as Hypotension in Early Infancy.
Hypokalemia
P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping.
Hypokalemia
P450c17 deficiency: clinical and molecular characterization of six patients.
Hypokalemia
Phenotype-genotype correlation in eight Chinese 17alpha-hydroxylase/17,20 lyase-deficiency patients with five novel mutations of CYP17A1 gene.
Hypokalemia
Phenotypic variation in a Chinese family with 46,XY and 46,XX 17?-hydroxylase deficiency.
Hypokalemia
Two novel heterozygous mutations in the CYP17A1 gene in a Chinese patient with 17?-hydroxylase 17,20-lyase deficiency.
Hypokalemia
Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency.
Hypospadias
Association of variants in genes involved in environmental chemical metabolism and risk of cryptorchidism and hypospadias.
Hypospadias
CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding.
Hypospadias
Defects of the testosterone biosynthetic pathway in boys with hypospadias.
Hypospadias
Hypospadias risk and polymorphism in SRD5A2 and CYP17 genes: case-control study among Indian children.
Hypospadias
Lack of defects in androgen production in children with hypospadias.
Hypospadias
Polymorphisms in the P450 c17 (17-Hydroxylase/17, 20-Lyase) Gene: Association with Estradiol and Testosterone Concentration in Hypospadias.
Hypospadias
The relationship between müllerian inhibiting substance and androgens in boys with hypospadias.
Hypotension
P450c17 Deficiency Caused by Compound Heterozygosity for Two Novel Mutations Presenting as Hypotension in Early Infancy.
Infections
Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome.
Infections
Cryptotanshinone Regulates Androgen Synthesis through the ERK/c-Fos/CYP17 Pathway in Porcine Granulosa Cells.
Infections
Effect of mice Taenia crassiceps WFU cysticerci infection on the ovarian folliculogenesis, enzyme expression, and serum estradiol.
Infections
Enzymatic activities of P450c17 stably expressed in fibroblasts from patients with the polycystic ovary syndrome.
Infertility
Familial partial 17,20-desmolase and 17alpha-hydroxylase deficiency presenting as infertility.
Infertility
Haploinsufficiency of cytochrome P450 17alpha-hydroxylase/17,20 lyase (CYP17) causes infertility in male mice.
Infertility
Polymorphic variants of CYP17 and CYP19A and risk of infertility in endometriosis.
Infertility
Structures of human steroidogenic cytochrome P450 17A1 with substrates.
Infertility, Male
Re: the polymorphism (-600 C>A) of CpG methylation site at the promoter region of CYP17A1 and its association of male infertility and testosterone levels.
Infertility, Male
The polymorphism (-600 C>A) of CpG methylation site at the promoter region of CYP17A1 and its association of male infertility and testosterone levels.
Insulin Resistance
17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss.
Insulin Resistance
An analysis of the relationship between insulin resistance and the activity of steroid C17,20-lyase and 3beta-hydroxysteroid dehydrogenase in ovaries and adrenals in women with polycystic ovary syndrome.
Insulin Resistance
Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity.
Insulin Resistance
Continuous administration of a P450 aromatase inhibitor induces polycystic ovary syndrome with a metabolic and endocrine phenotype in female rats at adult age.
Insulin Resistance
Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
Insulin Resistance
Enzymatic activities of P450c17 stably expressed in fibroblasts from patients with the polycystic ovary syndrome.
Insulin Resistance
Genetic Polymorphism CYP17 rs2486758 and Metabolic Risk Factors Predict Daily Salivary 17?-Estradiol Concentration in Healthy Premenopausal Norwegian Women. The EBBA-I Study.
Insulin Resistance
No association between CYP17 -34T/C polymorphism and insulin resistance in Thai polycystic ovary syndrome.
Insulin Resistance
Obesity-induced excess of 17-hydroxyprogesterone promotes hyperglycemia through activation of glucocorticoid receptor.
Insulin Resistance
Pathways leading to phosphorylation of p450c17 and to the posttranslational regulation of androgen biosynthesis.
Insulin Resistance
Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style?
Insulin Resistance
Polymorphism T --> C (-34 base pairs) of gene CYP17 promoter in women with polycystic ovary syndrome is associated with increased body weight and insulin resistance: a preliminary study.
Insulin Resistance
Role of cytochrome P450c17 in polycystic ovary syndrome.
Insulin Resistance
Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome.
Insulin Resistance
Steroidogenic alterations and adrenal androgen excess in PCOS.
Insulin Resistance
The regulation of human p450c17 activity: relationship to premature adrenarche, insulin resistance and the polycystic ovary syndrome.
Intestinal Obstruction
Hypokalemic crisis simulating intestinal obstruction in a 4-year-old girl. A consequence of 17alpha-hydroxylase deficiency.
Ischemic Stroke
Association between cytochrome P450 promoter polymorphisms and ischemic stroke.
Leiomyoma
A CYP17A1 gene polymorphism in association with multiple uterine leimyomas; a meta-analysis.
Leiomyoma
A possible role of the cytochrome P450c17alpha gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: a pilot study.
Leiomyoma
Association of the CYP17 gene polymorphism with risk for uterine leiomyoma in Brazilian women.
Leiomyoma
Distribution of CYP17? polymorphism and selected physiochemical factors of uterine leiomyoma in Barbados.
Leiomyoma
Genotype distribution of estrogen receptor-alpha, catechol-O-methyltransferase, and cytochrome P450 17 gene polymorphisms in Caucasian women with uterine leiomyomas.
Leiomyoma
Polymorphisms of CYP17A1, CYP19, and androgen in Brazilian women with uterine leiomyomas.
Leiomyoma
Risk for estrogen-dependent diseases in relation to phthalate exposure and polymorphisms of CYP17A1 and estrogen receptor genes.
Leiomyoma
Solitary and multiple uterine leiomyomas among caucasian women: Two different disorders?
Leiomyoma
The CYP17 MspA1 polymorphism is not associated with an increased risk of uterine leiomyomas in a Japanese population.
Leiomyoma
[Effects of metformin on the expression of estrogen synthetase and ER mRNA in uterine leiomyoma tissues].
Leukemia
Ontogeny of elongation and gene expression in the early developing porcine conceptus.
Leydig Cell Tumor
Expression of aromatase cytochrome P450 in rat H540 Leydig tumor cells.
Liver Neoplasms
Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients.
Lung Neoplasms
Association Between Polymorphisms in COMT, PLCH1, and CYP17A1, and Non-Small-Cell Lung Cancer Risk in Chinese Nonsmokers.
Lung Neoplasms
Concomitant occurence of multiple autoantibodies against human cytochromes P450.
Lung Neoplasms
Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women.
Lung Neoplasms
Transcriptome Analysis of WHV/c-myc Transgenic Mice Implicates Cytochrome P450 Enzyme 17A1 as a Promising Biomarker for Hepatocellular Carcinoma.
Lupus Erythematosus, Systemic
The polymorphic CYP17 allele is not found with increased frequency in systemic lupus erythematosus.
Lymphatic Metastasis
Evidence for steroidogenic potential in human prostate cell lines and tissues.
Lymphoma
Cytochrome P450 17 (CYP17) Is Involved in Endometrial Cancinogenesis Through Apoptosis and Invasion Pathways.
Lymphoma
Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk.
Lymphoma, B-Cell
Cytochrome P450 17 (CYP17) Is Involved in Endometrial Cancinogenesis Through Apoptosis and Invasion Pathways.
Lymphoma, Large B-Cell, Diffuse
Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk.
Lymphoma, Non-Hodgkin
Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk.
Lymphoma, Non-Hodgkin
Polymorphisms in cytochrome P450 17A1 and risk of non-Hodgkin lymphoma.
Malnutrition
Effect of periconceptional undernutrition in sheep on late gestation expression of mRNA and protein from genes involved in fetal adrenal steroidogenesis and placental prostaglandin production.
Malnutrition
Embryo number and periconceptional undernutrition in the sheep have differential effects on adrenal epigenotype, growth, and development.
Melanoma
Cytochrome P450 17 (CYP17) Is Involved in Endometrial Cancinogenesis Through Apoptosis and Invasion Pathways.
Metabolic Syndrome
Design and synthesis of functionalized piperazin-1yl-(E)-stilbenes as inhibitors of 17?-hydroxylase-C17,20-lyase (Cyp17).
Mouth Neoplasms
CYP17 and tumor necrosis factor-alpha gene polymorphisms are associated with risk of oral cancer in Chinese patients in Taiwan.
Muscle Weakness
P450C17 (CYP17) Deficiency in Native Mexican Patient with a Novel Mutation.
Muscular Diseases
Molecular basis of hypokalemic myopathy caused by 17alpha-hydroxylase/17,20-lyase deficiency.
Myelolipoma
17alpha-hydroxylase deficiency accompanied by adrenal myelolipoma.
Myelolipoma
Giant bilateral adrenal myelolipomas in two Chinese families with congenital adrenal hyperplasia.
Myocardial Infarction
CYP17A1 deficient XY mice display susceptibility to atherosclerosis, altered lipidomic profile and atypical sex development.
Myocardial Infarction
Genetic Variant in the CYP17 Gene and Risk of Premature Coronary Artery Disease.
Neoplasm Metastasis
CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1.
Neoplasm Metastasis
Evidence for steroidogenic potential in human prostate cell lines and tissues.
Neoplasm Metastasis
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Neoplasms
17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.
Neoplasms
A case of aldosterone-producing adrenocortical adenoma associated with a probable post-operative adrenal crisis: histopathological analyses of the adrenal gland.
Neoplasms
A CYP17A1 gene polymorphism in association with multiple uterine leimyomas; a meta-analysis.
Neoplasms
A novel communication role for CYP17A1 in the progression of castration-resistant prostate cancer.
Neoplasms
A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.
Neoplasms
A novel point mutation in P450c17 (CYP17) causing combined 17alpha-hydroxylase/17,20-lyase deficiency.
Neoplasms
Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.
Neoplasms
Adult granulosa cell tumors of the ovary: a retrospective study of 30 cases with respect to the expression of steroid synthesis enzymes.
Neoplasms
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
Neoplasms
Are CYP17 genotypes a biomarker for ovarian cancer in patients with cancer history in their family?
Neoplasms
Association between CYP17 gene polymorphism and risk of breast cancer in young women.
Neoplasms
Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients.
Neoplasms
Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
Neoplasms
Association of CYP17 genetic polymorphism with intra-tumoral estradiol concentrations but not with CYP17 messenger RNA levels in breast cancer tissue.
Neoplasms
Association of Cytochrome-17 (MspA1) Gene Polymorphism with Risk of Gall Bladder Stones and Cancer in North India.
Neoplasms
Benign cortisol-secreting adrenocortical adenomas produce small amounts of androgens.
Neoplasms
Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing.
Neoplasms
Biochemical, Histopathological, and Genetic Characterization of Posture-Responsive and Unresponsive APAs.
Neoplasms
Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility.
Neoplasms
cAMP-dependent transactivation involving the homeodomain protein Pbx1.
Neoplasms
Cellular localization of androgen synthesis in equine granulosa-theca cell tumors: Immunohistochemical expression of 17alpha-hydroxylase/17,20-lyase cytochrome P450.
Neoplasms
Chemopreventive actions by enterolactone and 13 VIOXX-related lactone derivatives in H295R human adrenocortical carcinoma cells.
Neoplasms
Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions.
Neoplasms
Current researches on breast cancer epidemiology in Korea.
Neoplasms
Cushing's Syndrome by Left Adrenocortical Adenoma Synchronously Associated with Primary Aldosteronism by Right Adrenocortical Adenoma: Report of a Case.
Neoplasms
Cushing's syndrome due to bilateral adrenocortical adenomas with different pathological features.
Neoplasms
CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1.
Neoplasms
CYP17 and tumor necrosis factor-alpha gene polymorphisms are associated with risk of oral cancer in Chinese patients in Taiwan.
Neoplasms
CYP17 Gene Polymorphism and its Association in North Indian Prostate Cancer Patients.
Neoplasms
CYP17 genetic polymorphism in patients with endometrial hyperplasia and cancer.
Neoplasms
CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).
Neoplasms
CYP17 genotype and breast cancer risk.
Neoplasms
CYP17 inhibition as a hormonal strategy for prostate cancer.
Neoplasms
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials.
Neoplasms
CYP17 MspA1 Gene Polymorphism and Breast Cancer Patients According to Age of Onset in Cancer Institute of Iran.
Neoplasms
CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China.
Neoplasms
CYP17 polymorphisms are associated with decreased risk of breast cancer in Chinese Han women: a case-control study.
Neoplasms
CYP17 promotor polymorphism and ovarian cancer risk.
Neoplasms
CYP17A1 and Androgen-Receptor Expression in Prostate Carcinoma Tissues and Cancer Cell Lines.
Neoplasms
CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
Neoplasms
Cytochrome b5 expression in gonadectomy-induced adrenocortical neoplasms of the domestic ferret (Mustela putorius furo).
Neoplasms
Cytochrome P450 17alpha hydroxylase/17,20 lyase (CYP17) function in cholesterol biosynthesis: identification of squalene monooxygenase (epoxidase) activity associated with CYP17 in Leydig cells.
Neoplasms
Dehydroepiandrosterone (DHEA)-SO4 Depot and Castration-Resistant Prostate Cancer.
Neoplasms
Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
Neoplasms
Discovery of inhibitors of MCF-7 tumor cell adhesion to endothelial cells and investigation on their mode of action.
Neoplasms
Disorganized Steroidogenesis in Adrenocortical Carcinoma, a Case Study.
Neoplasms
Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys.
Neoplasms
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.
Neoplasms
Effects of lentivirus-mediated CYP17A1 gene silencing on the biological activity of glioma.
Neoplasms
Endurance exercise and conjugated linoleic acid (CLA) supplementation up-regulate CYP17A1 and stimulate testosterone biosynthesis.
Neoplasms
Enhanced expression of mRNA coding for the adrenaline-synthesizing enzyme phenylethanolamine-N-methyl transferase in adrenaline-secreting pheochromocytomas.
Neoplasms
Evaluation of Cortisol Production in Aldosterone-Producing Adenoma.
Neoplasms
Evaluation of Local CYP17A1 and CYP19A1 Expression Levels as Prognostic Factors in Postmenopausal Invasive Ductal Breast Cancer Cases.
Neoplasms
Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer.
Neoplasms
Expression of aromatase cytochrome P450 in rat H540 Leydig tumor cells.
Neoplasms
Expression of steroidogenic enzymes and their transcription factors in cortisol-producing adrenocortical adenomas: immunohistochemical analysis and quantitative real-time polymerase chain reaction studies.
Neoplasms
Favourable response of a virilizing adrenocortical carcinoma to preoperative treatment with ketoconazole and postoperative chemotherapy.
Neoplasms
Features of the fetal gonad in androgen synthesis in the postpubertal testis are preserved in complete androgen insensitivity syndrome due to a novel genetic splice site donor variant in androgen receptor gene intron 1.
Neoplasms
Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers.
Neoplasms
Genetic variation in CYP17 and endometrial cancer risk.
Neoplasms
Genetic variation: effect on prostate cancer.
Neoplasms
Genetics, Structure, Function, Mode Of Actions And Role In Cancer Development Of Cyp17.
Neoplasms
Genomic Profiling of the Steroidogenic Acute Regulatory Protein in Breast Cancer: In Silico Assessments and a Mechanistic Perspective.
Neoplasms
Gonadectomy-related adrenocortical tumors in ferrets demonstrate increased expression of androgen and estrogen synthesizing enzymes together with high inhibin expression.
Neoplasms
Histological Characterization of Aldosterone-producing Adrenocortical Adenomas with Different Somatic Mutations.
Neoplasms
HPLC-RIA analysis of steroid hormone profile in a virilizing stromal tumor of the ovary.
Neoplasms
Incidentally discovered adrenocortical adenomas are not fully nonfunctioning: immunohistochemical and dispersed adrenocortical cell study.
Neoplasms
Increased 3?-hydroxysteroid dehydrogenase 2 and 17?-hydroxylase activities in a virilized adolescent female with adrenal adenoma: A case report.
Neoplasms
Increased expression of CYP17 and CYP11B1 in subclinical Cushing's syndrome due to adrenal adenomas.
Neoplasms
Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer.
Neoplasms
Increased ratio of mRNA expression of the genes CYP17 and CYP11B1 indicates autonomous cortisol production in adrenocortical tumours.
Neoplasms
Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Neoplasms
Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration Resistant Prostate Cancer and is Upregulated by Treatment with CYP17A1 Inhibitors.
Neoplasms
Intratumoral heterogeneity of the tumor cells based on in situ cortisol excess in cortisol-producing adenomas; ?An association among morphometry, genotype and cellular senescence?.
Neoplasms
Intratumoral steroid profiling of adrenal cortisol-producing adenomas by liquid chromatography- mass spectrometry.
Neoplasms
Investigating mineralocorticoid hypertension.
Neoplasms
Isolation and characterization of the mouse P450 17 alpha-hydroxylase/C17-20-lyase gene (Cyp17): transcriptional regulation of the gene by cyclic adenosine 3',5'-monophosphate in MA-10 Leydig cells.
Neoplasms
Leydig cell tumor of the testis: analysis of testosterone production and secretion by three-dimensional histoculture.
Neoplasms
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Neoplasms
MAMLD1 and 46,XY disorders of sex development.
Neoplasms
Mamld1 knockdown reduces testosterone production and Cyp17a1 expression in mouse Leydig tumor cells.
Neoplasms
Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency.
Neoplasms
Menstrual and reproductive factors in women, genetic variation in CYP17A1, and pancreatic cancer risk in the European prospective investigation into cancer and nutrition (EPIC) cohort.
Neoplasms
Modulation of expression of 17-Hydroxylase/17,20 lyase (CYP17) and P450 aromatase (CYP19) by inhibition of MEK1 in a human ovarian granulosa-like tumor cell line.
Neoplasms
Molecular characterization of a Leydig cell tumor presenting as congenital adrenal hyperplasia.
Neoplasms
New benzothieno[2,3-c]pyridines as non-steroidal CYP17 inhibitors: design, synthesis, anticancer screening, apoptosis induction, and in silico ADME profile studies.
Neoplasms
No association of the 5' promoter region polymorphism of CYP17 with breast cancer risk in Japan.
Neoplasms
Nuclear receptors and co-regulators in adrenal tumors.
Neoplasms
Orphan receptors COUP-TF and DAX-1 as targets in disordered CYP17 expression in adrenocortical tumors.
Neoplasms
Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
Neoplasms
Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk.
Neoplasms
Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer.
Neoplasms
Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model.
Neoplasms
Preclinical assessment of Orteronel(®), a CYP17A1 enzyme inhibitor in rats.
Neoplasms
Primary aldosteronism associated with subclinical Cushing syndrome.
Neoplasms
Progesterone 16 alpha-hydroxylase activity is catalyzed by human cytochrome P450 17 alpha-hydroxylase.
Neoplasms
Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
Neoplasms
Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
Neoplasms
Regulation of differential COUP-TF-coregulator interactions in adrenal cortical steroidogenesis.
Neoplasms
Renin-Independent hypermineralocorticoidism.
Neoplasms
Repression of cAMP-induced expression of the mouse P450 17 alpha-hydroxylase/C17-20 lyase gene (Cyp17) by androgens.
Neoplasms
Resistance to CYP17A1 inhibition with abiraterone in castration resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants.
Neoplasms
Single or Multiple Access Channels to the CYP450s Active Site? An Answer from Free Energy Simulations of the Human Aromatase Enzyme.
Neoplasms
Species-Specific Regulation of PXR/CAR/ER-Target Genes in the Mouse and Rat Liver Elicited by o,p'-DDT.
Neoplasms
Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
Neoplasms
Sporadic solitary aldosterone- and cortisol-co-secreting adenomas: endocrine, histological and genetic findings in a subtype of primary aldosteronism.
Neoplasms
Steroid cell tumor associated with primary amenorrhea and virilization.
Neoplasms
Steroid metabolism gene CYP17 polymorphism and the development of breast cancer.
Neoplasms
Steroid metabolism gene polymorphisms and their implications on breast and ovarian cancer prognosis.
Neoplasms
Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
Neoplasms
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
Neoplasms
Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
Neoplasms
Synthesis of novel C17 steroidal carbamates. Studies on CYP17 action, androgen receptor binding and function, and prostate cancer cell growth.
Neoplasms
Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of phenyl alkyl imidazole-based compounds as potent inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
Neoplasms
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
Neoplasms
The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
Neoplasms
The crosstalk between aldosterone and calcium metabolism in primary aldosteronism: A possible calcium metabolism-associated aberrant "neoplastic" steroidogenesis in adrenals.
Neoplasms
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.
Neoplasms
The effect of insulin and insulin-like growth factors on the expression of steroidogenic enzymes in a human ovarian thecal-like tumor cell model.
Neoplasms
The effect of transforming growth factor-beta on steroidogenesis and expression of key steroidogenic enzymes with a human ovarian thecal-like tumor cell model.
Neoplasms
The mechanism for protein kinase C inhibition of androgen production and 17alpha-hydroxylase expression in a theca cell tumor model.
Neoplasms
The post-translational regulation of 17,20 lyase activity.
Neoplasms
Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.
Neoplasms
Transcriptional regulation of the bovine CYP17 (P-450(17)alpha) gene. Identification of two cAMP regulatory regions lacking the consensus cAMP-responsive element (CRE).
Neoplasms
Tumor necrosis factor-alpha inhibition of 17 alpha-hydroxylase/C17-20 lyase gene (Cyp17) expression.
Neoplasms
Words of wisdom. Re: phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration- resistant prostate cancer commonly remains hormone driven.
Neoplasms
Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reid AH, Yap TA, et al. J Clin Oncol 2008;26:4563-71.
Neoplasms
Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper C, Kaye S, Dearnaley D, Lee G, de Bono JS. J Clin Oncol 2008;26:4563-71.
Neoplasms
Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Neoplasms
[A case-control study of environmental and genetic factors and prostate cancer in Guangdong]
Neoplasms
[Genetic polymorphism of steroid 17 alpha-hydroxylase/17,20-lyase (CYP17) and hyperinsulinemia in endometrial carcinoma]
Neoplasms
[Genetic polymorphism of steroidogenic enzymes and steroid receptor level in tumors of the reproductive system]
Neoplasms
[Interaction of novel oxazoline derivatives of 17(20)e-pregna-5,17(20)-diene with cytochrome P450 17A1].
Neoplasms
[Nuclear receptors in the pathophysiology of endocrine tumors]
Neoplasms, Germ Cell and Embryonal
A novel point mutation in P450c17 (CYP17) causing combined 17alpha-hydroxylase/17,20-lyase deficiency.
Neuralgia
Inhibition of cytochrome P450c17 reduces spinal astrocyte activation in a mouse model of neuropathic pain via regulation of p38 MAPK phosphorylation.
Neuralgia
Spinal cytochrome P450c17 plays a key role in the development of neuropathic mechanical allodynia: Involvement of astrocyte sigma-1 receptors.
Neuralgia
Spinal Interleukin-1? Inhibits Astrocyte Cytochrome P450c17 Expression Which Controls the Development of Mechanical Allodynia in a Mouse Model of Neuropathic Pain.
Neuralgia
Spinal Nitric Oxide Synthase Type II Increases Neurosteroid-metabolizing Cytochrome P450c17 Expression in a Rodent Model of Neuropathic Pain.
Neuroblastoma
Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor.
Neurodegenerative Diseases
Niemann pick type C disease as a model for defects in neurosteroidogenesis.
Neuroinflammatory Diseases
Suppressed oligodendrocyte steroidogenesis in multiple sclerosis: Implications for regulation of neuroinflammation.
Obesity
A family-based association study identified CYP17 as a candidate gene for obesity susceptibility in Caucasians.
Obesity
[Genetic aspects of polycystic ovary syndrome]
Oligospermia
The polymorphism (-600 C>A) of CpG methylation site at the promoter region of CYP17A1 and its association of male infertility and testosterone levels.
Osteoporosis
A family-based association study identified CYP17 as a candidate gene for obesity susceptibility in Caucasians.
Osteoporosis
Association of serum sex steroid levels and bone mineral density with CYP17 and CYP19 gene polymorphisms in postmenopausal women in Turkey.
Osteoporosis
Two single nucleotide polymorphisms in the CYP17 and COMT Genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy. The Danish Osteoporosis Prevention Study.
Osteoporosis
[Relationship of msp AI polymorphism in cytochrome P450c 17alpha gene with bone mass and bone size in Shanghai men of Han nationality]
Ovarian Cysts
Development of an early biomarker for the ovarian liability of selective estrogen receptor modulators in rats.
Ovarian Neoplasms
Are CYP17 genotypes a biomarker for ovarian cancer in patients with cancer history in their family?
Ovarian Neoplasms
CYP17 genotype and ovarian cancer: a null case-control study.
Ovarian Neoplasms
CYP17 promotor polymorphism and ovarian cancer risk.
Ovarian Neoplasms
Human Ovarian Cancer Stroma Contains Luteinized Theca Cells Harboring Tumor Suppressor Gene GT198 Mutations.
Ovarian Neoplasms
Ovarian cancer survival and polymorphisms in hormone and DNA repair pathway genes.
Ovarian Neoplasms
Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer.
Ovarian Neoplasms
The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Ovarian Torsion
Clinical, hormonal, ovarian, and genetic aspects of 46,XX patients with congenital adrenal hyperplasia due to CYP17A1 defects.
Overweight
CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China.
Pancreatic Neoplasms
Genetic variation in CYP17A1 and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California.
Pancreatic Neoplasms
Menstrual and reproductive factors in women, genetic variation in CYP17A1, and pancreatic cancer risk in the European prospective investigation into cancer and nutrition (EPIC) cohort.
Peripheral Nerve Injuries
Spinal cytochrome P450c17 plays a key role in the development of neuropathic mechanical allodynia: Involvement of astrocyte sigma-1 receptors.
Peripheral Nerve Injuries
Spinal Interleukin-1? Inhibits Astrocyte Cytochrome P450c17 Expression Which Controls the Development of Mechanical Allodynia in a Mouse Model of Neuropathic Pain.
Peripheral Nerve Injuries
Spinal Nitric Oxide Synthase Type II Increases Neurosteroid-metabolizing Cytochrome P450c17 Expression in a Rodent Model of Neuropathic Pain.
Peripheral Nervous System Diseases
Inhibition of cytochrome P450c17 reduces spinal astrocyte activation in a mouse model of neuropathic pain via regulation of p38 MAPK phosphorylation.
Pheochromocytoma
Enhanced expression of mRNA coding for the adrenaline-synthesizing enzyme phenylethanolamine-N-methyl transferase in adrenaline-secreting pheochromocytomas.
Polycystic Ovary Syndrome
17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss.
Polycystic Ovary Syndrome
Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome.
Polycystic Ovary Syndrome
An analysis of the relationship between insulin resistance and the activity of steroid C17,20-lyase and 3beta-hydroxysteroid dehydrogenase in ovaries and adrenals in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Association of CYP17A1 gene -34T/C polymorphism with polycystic ovary syndrome in Han Chinese population.
Polycystic Ovary Syndrome
Association of the CYP17 and CYP19 gene polymorphisms in women with polycystic ovary syndrome from Punjab, Pakistan.
Polycystic Ovary Syndrome
Association study for single nucleotide polymorphisms in the CYP17A1 gene and polycystic ovary syndrome.
Polycystic Ovary Syndrome
Association Study of CYP17 and HSD11B1 in Polycystic Ovary Syndrome Utilizing Comprehensive Gene Coverage.
Polycystic Ovary Syndrome
CYP11A1 and CYP17 promoter polymorphisms associate with hyperandrogenemia in polycystic ovary syndrome.
Polycystic Ovary Syndrome
CYP17 gene polymorphic sequence variation is associated with hyperandrogenism in Kashmiri women with polycystic ovarian syndrome.
Polycystic Ovary Syndrome
Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells.
Polycystic Ovary Syndrome
Early steps in androgen biosynthesis: from cholesterol to DHEA.
Polycystic Ovary Syndrome
Enzymatic activities of P450c17 stably expressed in fibroblasts from patients with the polycystic ovary syndrome.
Polycystic Ovary Syndrome
Genetic association study from North India to analyze association of CYP19A1 and CYP17A1 with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Inhibin and activin differentially regulate androgen production and 17 alpha-hydroxylase expression in human ovarian thecal-like tumor cells.
Polycystic Ovary Syndrome
Inhibition of autophagy in theca cells induces CYP17A1 and PAI-1 expression via ROS/p38 and JNK signalling during the development of polycystic ovary syndrome.
Polycystic Ovary Syndrome
Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5'-UTR in patients with polycystic ovarian syndrome.
Polycystic Ovary Syndrome
Lack of relationship between 17-hydroxyprogesterone response to buserelin testing and hyperinsulinemia in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens.
Polycystic Ovary Syndrome
Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency.
Polycystic Ovary Syndrome
No association between CYP17 -34T/C polymorphism and insulin resistance in Thai polycystic ovary syndrome.
Polycystic Ovary Syndrome
Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
Polycystic Ovary Syndrome
Polymorphism T --> C (-34 base pairs) of gene CYP17 promoter in women with polycystic ovary syndrome is associated with increased body weight and insulin resistance: a preliminary study.
Polycystic Ovary Syndrome
Polymorphism T-->C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Polymorphism T?C of gene CYP17 promoter and polycystic ovary syndrome risk: a meta-analysis.
Polycystic Ovary Syndrome
Relationship of Biological Markers of Body Fat Distribution and Corticosteroidogenic Enzyme Activities in Women with Polycystic Ovary Syndrome.
Polycystic Ovary Syndrome
Resistin stimulation of 17alpha-hydroxylase activity in ovarian theca cells in vitro: relevance to polycystic ovary syndrome.
Polycystic Ovary Syndrome
Role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Role of cytochrome P450c17 in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome.
Polycystic Ovary Syndrome
The CYP17 MSP AI (T-34C) and CYP19A1 (Trp39Arg) variants in polycystic ovary syndrome: A case-control study.
Polycystic Ovary Syndrome
The Involvement of Granulosa Cells in the Regulation by Gonadotropins of Cyp17a1 in Theca Cells.
Polycystic Ovary Syndrome
The molecular basis of isolated 17,20 lyase deficiency.
Polycystic Ovary Syndrome
The post-translational regulation of 17,20 lyase activity.
Polycystic Ovary Syndrome
The regulation of human p450c17 activity: relationship to premature adrenarche, insulin resistance and the polycystic ovary syndrome.
Polycystic Ovary Syndrome
The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.
Polycystic Ovary Syndrome
The single-nucleotide polymorphism rs743572 of CYP17A1 shows significant association with polycystic ovary syndrome: a meta-analysis.
Polycystic Ovary Syndrome
[Effect of Transcutaneuos Acupoint Electrostimulation on Serum Sex Hormone Levels and Expression of Ovarian Steroid Hormone Metabolic Enzymes in Polycystic Ovary Syndrome Rats].
Polycystic Ovary Syndrome
[Polymorphism in CYP11alpha and CYP17 genes and the etiology of hyperandrogenism in patients with polycystic ovary syndrome]
Polycythemia
CYP17A1 and CYP2E1 variants associated with high altitude polycythemia in Tibetans at the Qinghai-Tibetan Plateau.
Polyendocrinopathies, Autoimmune
3beta-hydroxysteroid dehydrogenase autoantibodies are rare in premature ovarian failure.
Polyendocrinopathies, Autoimmune
Autoimmune regulator induced changes in the gene expression profile of human monocyte-dendritic cell-lineage.
Polyendocrinopathies, Autoimmune
Immunoprecipitation of steroidogenic enzyme autoantigens with autoimmune polyglandular syndrome type I (APS I) sera; further evidence for independent humoral immunity to P450c17 and P450c21.
Polyendocrinopathies, Autoimmune
Novel AIRE mutations and P450 cytochrome autoantibodies in Central and Eastern European patients with APECED.
Pre-Eclampsia
Exploration of CYP21A2 and CYP17A1 polymorphisms and preeclampsia risk among Chinese Han population: a large-scale case-control study based on 5021 subjects.
Pre-Eclampsia
Genetic polymorphism of catechol-O-methyltransferase and cytochrome P450c17? in preeclampsia.
Primary Ovarian Insufficiency
Adrenal-cortex autoantibodies and steroid-producing cells autoantibodies in patients with Addison's disease: comparison of immunofluorescence and immunoprecipitation assays.
Primary Ovarian Insufficiency
Autoantibody responses in autoimmune ovarian insufficiency and in Addison's disease are IgG1 dominated and suggest a predominant, but not exclusive, Th1 type of response.
Primary Ovarian Insufficiency
Steroid-cell autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity.
Primary Ovarian Insufficiency
The significance of polymorphism and expression of oestrogen metabolism-related genes in Chinese women with premature ovarian insufficiency.
Prostatic Hyperplasia
A polymorphism in the CYP17 gene is associated with prostate cancer risk.
Prostatic Hyperplasia
Association of CYP1A1, CYP1B1 and CYP17 gene polymorphisms and organochlorine pesticides with benign prostatic hyperplasia.
Prostatic Hyperplasia
Associations of SRD5A2/CYP17/CYP19/VDR gene polymorphisms with the development and clinical progression of benign prostatic hyperplasia: a case-control study in northern Chinese population.
Prostatic Hyperplasia
CYP17 Gene Polymorphism and its Association in North Indian Prostate Cancer Patients.
Prostatic Hyperplasia
Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia.
Prostatic Hyperplasia
CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
Prostatic Hyperplasia
Evidence for steroidogenic potential in human prostate cell lines and tissues.
Prostatic Hyperplasia
Genetic polymorphism in sex hormone metabolism and prostate cancer risk.
Prostatic Hyperplasia
Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
Prostatic Hyperplasia
Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Prostatic Hyperplasia
Role of CYP17 rs743572 Polymorphism in Benign Prostatic Hyperplasia: A Multivariate Integrated Analysis.
Prostatic Neoplasms
17(E)-picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies.
Prostatic Neoplasms
17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.
Prostatic Neoplasms
17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review.
Prostatic Neoplasms
4-pregnene-3-one-20 beta-carboxaldehyde: a potent inhibitor of 17 alpha-hydroxylase/C17,20-lyase and of 5 alpha-reductase.
Prostatic Neoplasms
A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
Prostatic Neoplasms
A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21.
Prostatic Neoplasms
A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
A novel communication role for CYP17A1 in the progression of castration-resistant prostate cancer.
Prostatic Neoplasms
A novel molecular modelling study of inhibitors of the 17alpha-hydroxylase component of the enzyme system 17alpha-hydroxylase/17,20-lyase (P-450(17alpha)).
Prostatic Neoplasms
A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.
Prostatic Neoplasms
A polymorphism in the CYP17 gene and risk of prostate cancer.
Prostatic Neoplasms
A polymorphism in the CYP17 gene is associated with prostate cancer risk.
Prostatic Neoplasms
A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.
Prostatic Neoplasms
A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone.
Prostatic Neoplasms
A2 Allele Polymorphism of the CYP17 Gene and Prostate Cancer Risk in an Iranian Population.
Prostatic Neoplasms
Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines.
Prostatic Neoplasms
Abiraterone acetate in metastatic castration-resistant prostate cancer: A retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.
Prostatic Neoplasms
Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency.
Prostatic Neoplasms
Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
Prostatic Neoplasms
Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.
Prostatic Neoplasms
Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Abiraterone in metastatic salivary duct carcinoma.
Prostatic Neoplasms
Abiraterone inhibits 1?,25-dihydroxyvitamin D3 metabolism by CYP3A4 in human liver and intestine in vitro.
Prostatic Neoplasms
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
Prostatic Neoplasms
Allelic frequencies of six polymorphic markers for risk of prostate cancer.
Prostatic Neoplasms
Androgen metabolism genes in prostate cancer health disparities.
Prostatic Neoplasms
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
Prostatic Neoplasms
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
Prostatic Neoplasms
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Androgens and the molecular epidemiology of prostate cancer.
Prostatic Neoplasms
Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Prostatic Neoplasms
Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells.
Prostatic Neoplasms
Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer.
Prostatic Neoplasms
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.
Prostatic Neoplasms
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
Prostatic Neoplasms
AR-v7 liquid biopsy for treatment stratification in prostate cancer: how close are we?
Prostatic Neoplasms
Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients.
Prostatic Neoplasms
Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
Prostatic Neoplasms
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.
Prostatic Neoplasms
Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer.
Prostatic Neoplasms
Association of Polymorphisms in the VDR, CYP17 and SRD5A2 Genes and Prostate Cancer Among Lebanese Men
Prostatic Neoplasms
Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
Prostatic Neoplasms
Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis.
Prostatic Neoplasms
Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population.
Prostatic Neoplasms
Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate.
Prostatic Neoplasms
Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing.
Prostatic Neoplasms
Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway.
Prostatic Neoplasms
CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.
Prostatic Neoplasms
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.
Prostatic Neoplasms
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
Prostatic Neoplasms
Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions.
Prostatic Neoplasms
Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Comparative Study of the Binding Mode between Cytochrome P450 17A1 and Prostate Cancer Drugs in the Absence of Haem Iron.
Prostatic Neoplasms
Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular Dynamics.
Prostatic Neoplasms
Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.
Prostatic Neoplasms
Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
Prostatic Neoplasms
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
Prostatic Neoplasms
CYP17 Gene Polymorphism and its Association in North Indian Prostate Cancer Patients.
Prostatic Neoplasms
CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population.
Prostatic Neoplasms
CYP17 gene polymorphisms and prostate cancer risk: A meta-analysis based on 38 independent studies.
Prostatic Neoplasms
CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies.
Prostatic Neoplasms
CYP17 gene promoter allelic variant is not associated with prostate cancer.
Prostatic Neoplasms
Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia.
Prostatic Neoplasms
CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).
Prostatic Neoplasms
CYP17 inhibition as a hormonal strategy for prostate cancer.
Prostatic Neoplasms
CYP17 inhibitors for prostate cancer therapy.
Prostatic Neoplasms
CYP17 inhibitors for prostate cancer treatment--an update.
Prostatic Neoplasms
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials.
Prostatic Neoplasms
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential.
Prostatic Neoplasms
CYP17 polymorphisms and prostate cancer outcomes.
Prostatic Neoplasms
CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
Prostatic Neoplasms
Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans.
Prostatic Neoplasms
CYP17 T27C polymorphism and prostate cancer risk: a meta-analysis based on 31 studies.
Prostatic Neoplasms
CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population.
Prostatic Neoplasms
CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
Prostatic Neoplasms
CYP17A1 inhibitors in castration-resistant prostate cancer.
Prostatic Neoplasms
CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.
Prostatic Neoplasms
CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone.
Prostatic Neoplasms
CYP17A1: a biochemistry, chemistry, and clinical review.
Prostatic Neoplasms
Cytochrome b5 Activates the 17,20-Lyase Activity of Human Cytochrome P450 17A1 by Increasing the Coupling of NADPH Consumption to Androgen Production.
Prostatic Neoplasms
Cytochrome P450 17A1 Inhibitor Abiraterone Acetate Counteracts the Heat Shock Protein 27's Cell Survival Properties in Prostate Cancer Cells.
Prostatic Neoplasms
Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways.
Prostatic Neoplasms
Design and synthesis of functionalized piperazin-1yl-(E)-stilbenes as inhibitors of 17?-hydroxylase-C17,20-lyase (Cyp17).
Prostatic Neoplasms
Development of a simple and rapid assay for the evaluation of inhibitors of human 17alpha-hydroxylase-C(17,20)-lyase (P450cl7) by coexpression of P450cl7 with NADPH-cytochrome-P450-reductase in Escherichia coli.
Prostatic Neoplasms
Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.
Prostatic Neoplasms
Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.
Prostatic Neoplasms
Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.
Prostatic Neoplasms
Discovery of Novel Non-Steroidal Cytochrome P450 17A1 Inhibitors as Potential Prostate Cancer Agents.
Prostatic Neoplasms
Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer.
Prostatic Neoplasms
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Effect of CYP17 and PSA gene polymorphisms on prostate cancer risk and circulating PSA levels in the Slovak population.
Prostatic Neoplasms
Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.
Prostatic Neoplasms
Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Prostatic Neoplasms
Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer.
Prostatic Neoplasms
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials.
Prostatic Neoplasms
Erratum to: Association of a CYP17 Polymorphism With Overall Survival in Caucasian Patients With Androgen-independent Prostate Cancer.
Prostatic Neoplasms
Evidence that cytochrome b5 acts as a redox donor in CYP17A1 mediated androgen synthesis.
Prostatic Neoplasms
Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation.
Prostatic Neoplasms
Functional characterization of the G162R and D216H genetic variants of human CYP17A1.
Prostatic Neoplasms
Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.
Prostatic Neoplasms
Genetic polymorphism in sex hormone metabolism and prostate cancer risk.
Prostatic Neoplasms
Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
Prostatic Neoplasms
Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy.
Prostatic Neoplasms
Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers.
Prostatic Neoplasms
Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
Prostatic Neoplasms
Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation.
Prostatic Neoplasms
Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate Cancer.
Prostatic Neoplasms
Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
Prostatic Neoplasms
Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition.
Prostatic Neoplasms
Hormonal carcinogenesis.
Prostatic Neoplasms
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer.
Prostatic Neoplasms
HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer.
Prostatic Neoplasms
Human Cytochrome CYP17A1: The Structural Basis for Compromised Lyase Activity with 17-Hydroxyprogesterone.
Prostatic Neoplasms
Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta.
Prostatic Neoplasms
Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1.
Prostatic Neoplasms
Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC).
Prostatic Neoplasms
Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer.
Prostatic Neoplasms
Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Prostatic Neoplasms
Inherited variation in hormone-regulating genes and prostate cancer survival.
Prostatic Neoplasms
Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone.
Prostatic Neoplasms
Inhibition of CYP17A1 activity by resveratrol, piceatannol, and synthetic resveratrol analogs.
Prostatic Neoplasms
Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate.
Prostatic Neoplasms
Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer.
Prostatic Neoplasms
Interactions of abiraterone, eplerenone and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Prostatic Neoplasms
Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration Resistant Prostate Cancer and is Upregulated by Treatment with CYP17A1 Inhibitors.
Prostatic Neoplasms
Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
Prostatic Neoplasms
Lack of association between CYP17 Mspa1 polymorphism and prostate cancer risk: a meta-analysis of 14494 cases and 15971 controls.
Prostatic Neoplasms
Limited expression of cytochrome p450 17?-hydroxylase/17,20-lyase in prostate cancer cell lines.
Prostatic Neoplasms
Limited in vitro efficacy of CYP17A1 inhibition on human castration resistant prostate cancer.
Prostatic Neoplasms
Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer.
Prostatic Neoplasms
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
Prostatic Neoplasms
Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency.
Prostatic Neoplasms
Mechanistic Scrutiny Identifies a Kinetic Role for Cytochrome b5 Regulation of Human Cytochrome P450c17 (CYP17A1, P450 17A1).
Prostatic Neoplasms
Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.
Prostatic Neoplasms
Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Prostatic Neoplasms
Molecular Pathways: Inhibiting steroid biosynthesis in prostate cancer.
Prostatic Neoplasms
New benzothieno[2,3-c]pyridines as non-steroidal CYP17 inhibitors: design, synthesis, anticancer screening, apoptosis induction, and in silico ADME profile studies.
Prostatic Neoplasms
New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches.
Prostatic Neoplasms
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.
Prostatic Neoplasms
No association of the 5' promoter region polymorphism of CYP17 gene with prostate cancer risk.
Prostatic Neoplasms
No Relationship of Anti-Androgens to Alzheimer's Disease or Cognitive Disorder in the MedWatch Database.
Prostatic Neoplasms
Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: a Survey on Chemical Structures Binding this Fast-Mutating Target.
Prostatic Neoplasms
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Prostatic Neoplasms
Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.
Prostatic Neoplasms
Novel oxazolinyl derivatives of pregna-5,17(20)-diene as 17?-hydroxylase/17,20-lyase (CYP17A1) inhibitors.
Prostatic Neoplasms
ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.
Prostatic Neoplasms
Orteronel for the treatment of prostate cancer.
Prostatic Neoplasms
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Prostatic Neoplasms
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Prostatic Neoplasms
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.
Prostatic Neoplasms
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.
Prostatic Neoplasms
PI-3 kinase p110?: a therapeutic target in advanced prostate cancers.
Prostatic Neoplasms
Polymorphism in the Androgen Biosynthesis Gene (CYP17), a Risk for Prostate Cancer: A Meta-Analysis.
Prostatic Neoplasms
Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy.
Prostatic Neoplasms
Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent.
Prostatic Neoplasms
Polymorphisms of Estrogen Metabolism-Related Genes and Prostate Cancer Risk in Two Populations of African Ancestry.
Prostatic Neoplasms
Polymorphisms of metabolic enzyme genes, living habits and prostate cancer susceptibility.
Prostatic Neoplasms
Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model.
Prostatic Neoplasms
Pretreatment Neutrophil-to-Lymphocyte Ratio in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Ketoconazole: Association with Outcome and Predictive Nomogram.
Prostatic Neoplasms
Prevalent mutations in prostate cancer.
Prostatic Neoplasms
Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors.
Prostatic Neoplasms
Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
Prostatic Neoplasms
Prostate cancer associated with CYP17 genotype.
Prostatic Neoplasms
Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Prostatic Neoplasms
Prostate Cancer with Variants in CYP17 and UGT2B17 Genes: A Meta-Analysis.
Prostatic Neoplasms
Prostate cancer: CYP17A1 inhibitor failure-lessons for future drug development.
Prostatic Neoplasms
Prostate cancer: The influence of steroid metabolism on CYP17A1 inhibitor activity.
Prostatic Neoplasms
PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy.
Prostatic Neoplasms
Quantitative Assessment of the Association Between CYP17 rs743572 Polymorphism and Prostate Cancer Risk.
Prostatic Neoplasms
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.
Prostatic Neoplasms
Relationship between CYP17 gene polymorphisms and risk of prostate cancer.
Prostatic Neoplasms
Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Prostatic Neoplasms
Resistance to CYP17A1 inhibition with abiraterone in castration resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants.
Prostatic Neoplasms
Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone.
Prostatic Neoplasms
Review of studies on metabolic genes and cancer in populations of African descent.
Prostatic Neoplasms
Revising the role of the androgen receptor in breast cancer.
Prostatic Neoplasms
Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany.
Prostatic Neoplasms
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.
Prostatic Neoplasms
Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population.
Prostatic Neoplasms
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.
Prostatic Neoplasms
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Prostatic Neoplasms
Serum level of IGFBP3 and IGF1/IGFBP3 molar ratio in addition to PSA and single nucleotide polymorphism in PSA and CYP17 gene may contribute to early diagnostics of prostate cancer.
Prostatic Neoplasms
Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
Prostatic Neoplasms
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Prostatic Neoplasms
Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
Prostatic Neoplasms
Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
Prostatic Neoplasms
Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
Prostatic Neoplasms
Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.
Prostatic Neoplasms
Strategies to Circumvent Testosterone Surge and Disease Flare in Advanced Prostate Cancer: Emerging Treatment Paradigms.
Prostatic Neoplasms
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
Prostatic Neoplasms
Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors.
Prostatic Neoplasms
Synthesis and evaluation of pregnane derivatives as inhibitors of human testicular 17 alpha-hydroxylase/C17,20-lyase.
Prostatic Neoplasms
Synthesis of novel C17 steroidal carbamates. Studies on CYP17 action, androgen receptor binding and function, and prostate cancer cell growth.
Prostatic Neoplasms
Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Prostatic Neoplasms
Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.
Prostatic Neoplasms
Targeting CYP17: established and novel approaches in prostate cancer.
Prostatic Neoplasms
Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy.
Prostatic Neoplasms
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
Prostatic Neoplasms
The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
Prostatic Neoplasms
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.
Prostatic Neoplasms
The development of abiraterone acetate for castration-resistant prostate cancer.
Prostatic Neoplasms
The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.
Prostatic Neoplasms
The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
Prostatic Neoplasms
The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition.
Prostatic Neoplasms
The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels.
Prostatic Neoplasms
Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.
Prostatic Neoplasms
Transcriptome Analysis of WHV/c-myc Transgenic Mice Implicates Cytochrome P450 Enzyme 17A1 as a Promising Biomarker for Hepatocellular Carcinoma.
Prostatic Neoplasms
TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.
Prostatic Neoplasms
Upregulation of CYP17A1 by Sp1-mediated DNA demethylation confers temozolomide resistance through DHEA-mediated protection in glioma.
Prostatic Neoplasms
Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Words of wisdom. Re: phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration- resistant prostate cancer commonly remains hormone driven.
Prostatic Neoplasms
Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reid AH, Yap TA, et al. J Clin Oncol 2008;26:4563-71.
Prostatic Neoplasms
Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper C, Kaye S, Dearnaley D, Lee G, de Bono JS. J Clin Oncol 2008;26:4563-71.
Prostatic Neoplasms
Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Prostatic Neoplasms
[A case-control study of environmental and genetic factors and prostate cancer in Guangdong]
Prostatic Neoplasms
[Association between the polymorphism of CYP17 gene and risk of prostate cancer in chinese vigurs men]
Prostatic Neoplasms
[Molecular epidemiology and cancer prevention]
Pseudohypoaldosteronism
Epidemiologic study of adrenal gland disorders in Japan.
Puberty, Delayed
A rare cause of delayed puberty in two cases with 46,XX and 46,XY karyotype: 17 ?-hydroxylase deficiency due to a novel variant in CYP17A1 gene.
Puberty, Delayed
P450c17 deficiency: clinical and molecular characterization of six patients.
Puberty, Precocious
Are CYP1A1, CYP17 and CYP1B1 mutation genes involved on girls with precocious puberty? A pilot study.
Rectal Neoplasms
Cytochrome P450 17A1 and catechol O-methyltransferase polymorphisms and age at Lynch syndrome colon cancer onset in Newfoundland.
Scoliosis
Prediction of curve progression in idiopathic scoliosis from gene polymorphic analysis.
Sepsis
Sepsis produces depression of testosterone and steroidogenic acute regulatory (StAR) protein.
Sertoli Cell-Only Syndrome
Leydig cell dysfunction is associated with post-transcriptional deregulation of CYP17A1 in men with Sertoli cell-only syndrome.
Sexual Infantilism
A compound heterozygous mutation in the CYP17 (17alpha-hydroxylase/17,20-lyase) gene in a Chinese subject with congenital adrenal hyperplasia.
Sexual Infantilism
A novel compound heterozygous mutation in the CYP17 (P450 17alpha-hydroxylase) gene leading to 17alpha-hydroxylase/17,20-lyase deficiency.
Sexual Infantilism
A novel compound heterozygous mutation of K494_V495 deletion plus R496L and D487_F489 deletion in extreme C-terminus of cytochrome P450c17 causes 17alpha-hydroxylase deficiency.
Sexual Infantilism
A review of the literature on common CYP17A1 mutations in adults with 17-hydroxylase/17,20-lyase deficiency, a case series of such mutations among Koreans and functional characteristics of a novel mutation.
Sexual Infantilism
Clinical characteristics and mutation analysis of two Chinese children with 17a-hydroxylase/17,20-lyase deficiency.
Sexual Infantilism
Combined 17 alpha-hydroxylase/17,20-lyase deficiency due to a homozygous 25 BP duplication (NT 4157-4181) at exon 5 in the CYP17 resulting in a premature stop codon predicted by molecular modeling.
Sexual Infantilism
Disorders of androgen synthesis--from cholesterol to dehydroepiandrosterone.
Sexual Infantilism
Female phenotype with male karyotype: a clinical enigma.
Sexual Infantilism
Novel mutation in cytochrome P450c17 causes complete combined 17alpha-hydroxylase/17,20-lyase deficiency.
Sexual Infantilism
Novel P450c17 mutation H373D causing combined 17alpha-hydroxylase/17,20-lyase deficiency.
Sexual Infantilism
Phenotype-genotype correlation in eight Chinese 17alpha-hydroxylase/17,20 lyase-deficiency patients with five novel mutations of CYP17A1 gene.
Sexual Infantilism
Phenotypic variation in a Chinese family with 46,XY and 46,XX 17?-hydroxylase deficiency.
Sexual Infantilism
Regulation of P450c17 expression in the early embryo depends on GATA factors.
Sexual Infantilism
The genetics, pathophysiology, and management of human deficiencies of P450c17.
Sexual Infantilism
Two novel heterozygous mutations in the CYP17A1 gene in a Chinese patient with 17?-hydroxylase 17,20-lyase deficiency.
Spondylarthropathies
Association of CYP17 with HLA-B27-negative seronegative spondyloarthropathy in Japanese males.
Starvation
Impact of differential P450c17 phosphorylation by cAMP stimulation and by starvation conditions on enzyme activities and androgen production in NCI-H295R cells.
Starvation
Retinoic acid receptor beta and angiopoietin-like protein 1 are involved in the regulation of human androgen biosynthesis.
Starvation
Role of AMP-activated protein kinase on steroid hormone biosynthesis in adrenal NCI-H295R cells.
steroid 11beta-monooxygenase deficiency
Congenital adrenal hyperplasia and P450 oxidoreductase deficiency.
steroid 11beta-monooxygenase deficiency
Targeted gene panel sequencing for molecular diagnosis of congenital adrenal hyperplasia.
steroid 17alpha-monooxygenase deficiency
A novel mutation in CYP17A1 gene leads to congenital adrenal hyperplasia: A case report.
steroid 17alpha-monooxygenase deficiency
A review of the literature on common CYP17A1 mutations in adults with 17-hydroxylase/17,20-lyase deficiency, a case series of such mutations among Koreans and functional characteristics of a novel mutation.
steroid 17alpha-monooxygenase deficiency
A single amino acid substitution in the putative redox partner-binding site of P450c17 as cause of isolated 17,20-lyase deficiency.
steroid 17alpha-monooxygenase deficiency
A single-amino-acid in-frame deletion in CYP17A1 results in combined 17-hydroxylase and 17,20-lyase deficiency in an Iranian family despite the protein mutation site.
steroid 17alpha-monooxygenase deficiency
CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding.
steroid 17alpha-monooxygenase deficiency
Differential inhibition of 17alpha-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency.
steroid 17alpha-monooxygenase deficiency
Fertility in patients with genetic deficiencies of cytochrome P450c17 (CYP17A1): combined 17-hydroxylase/17,20-lyase deficiency and isolated 17,20-lyase deficiency.
steroid 17alpha-monooxygenase deficiency
Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency.
steroid 17alpha-monooxygenase deficiency
Isolated 17,20-lyase deficiency due to the cytochrome b5 mutation W27X.
steroid 17alpha-monooxygenase deficiency
Isolated 17,20-Lyase Deficiency in a CYB5A Mutated Female With Normal Sexual Development and Fertility.
steroid 17alpha-monooxygenase deficiency
Metabolic evidence for impaired 17alpha-hydroxylase activity in a kindred bearing the E305G mutation for isolate 17,20-lyase activity.
steroid 17alpha-monooxygenase deficiency
Pitfalls in characterizing P450c17 mutations associated with isolated 17,20-lyase deficiency.
steroid 17alpha-monooxygenase deficiency
Puberty in a case with novel 17-hydroxylase mutation and the putative role of estrogen in development of pubic hair.
steroid 17alpha-monooxygenase deficiency
Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic.
steroid 17alpha-monooxygenase deficiency
Steroid 17alpha-hydroxylase deficiency: functional characterization of four mutations (A174E, V178D, R440C, L465P) in the CYP17A1 gene.
steroid 17alpha-monooxygenase deficiency
Successful Delivery in 17,20-Lyase Deficiency.
steroid 17alpha-monooxygenase deficiency
The genetic and functional basis of isolated 17,20-lyase deficiency.
steroid 17alpha-monooxygenase deficiency
Towards a unifying mechanism for CYP17 mutations that cause isolated 17,20-lyase deficiency.
steroid 17alpha-monooxygenase deficiency
Two novel heterozygous mutations in the CYP17A1 gene in a Chinese patient with 17?-hydroxylase 17,20-lyase deficiency.
steroid 21-monooxygenase deficiency
Congenital adrenal hyperplasia and P450 oxidoreductase deficiency.
steroid 21-monooxygenase deficiency
Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study.
steroid 21-monooxygenase deficiency
Delayed diagnosis of disorder of sex development (DSD) due to P450 oxidoreductase (POR) deficiency.
steroid 21-monooxygenase deficiency
Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P.
steroid 21-monooxygenase deficiency
Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect.
steroid 21-monooxygenase deficiency
Pubertal Presentation in Seven Patients with Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency.
Stomach Neoplasms
Cholesterol import and steroidogenesis are biosignatures for gastric cancer patient survival.
Stomach Neoplasms
Genetic susceptibility factors on genes involved in the steroid hormone biosynthesis pathway and progesterone receptor for gastric cancer risk.
Stomach Neoplasms
Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer.
Stuttering
Sex steroid hormones and sex hormone binding globulin levels, CYP17 MSP AI (-34T:C) and CYP19 codon 39 (Trp:Arg) variants in children with developmental stuttering.
Tardive Dyskinesia
Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia.
Testicular Neoplasms
Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the testis.
Thecoma
The mechanism for protein kinase C inhibition of androgen production and 17alpha-hydroxylase expression in a theca cell tumor model.
Thrombophilia
Genetic factors in fetal growth restriction and miscarriage.
Triple Negative Breast Neoplasms
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
Triple Negative Breast Neoplasms
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
Turner Syndrome
Absence of autoantibodies connected to autoimmune polyendocrine syndrome type I and II and Addison's disease in girls and women with Turner syndrome.
Turner Syndrome
Adrenal-cortex autoantibodies and steroid-producing cells autoantibodies in patients with Addison's disease: comparison of immunofluorescence and immunoprecipitation assays.
Urinary Incontinence
Genetic susceptibility to urinary incontinence: implication of polymorphisms of androgen and oestrogen pathways.
Varicocele
Progesterone, 17-OH-progesterone, androstenedione and testosterone plasma levels in spermatic venous blood of normal men and varicocele patients.
Wilms Tumor
New frontiers on the molecular underpinnings of hypospadias according to severity.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1.14.14.32 17alpha-hydroxyprogesterone deacetylase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
